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Autoimmune diseases (ADs) represent a heterogeneous group of disorders that affect
specific target organs or multiple organ systems. These conditions share common immuno-
pathogenic mechanisms (i.e., the autoimmune tautology), which explain the clinical similari-
ties they have among them as well as their familial clustering (i.e., coaggregation). As part of
the autoimmune tautology, the influence of environmental exposure on the risk of developing
ADs is paramount (i.e., the autoimmune ecology). In fact, environment, more than genetics,
shapes immune system. Autoimmune ecology is akin to exposome, that is all the expo-
sures – internal and external – across the lifespan, interacting with hereditary factors (both
genetics and epigenetics) to favor or protect against autoimmunity and its outcomes. Herein,
we provide an overview of the autoimmune ecology, focusing on the immune response
to environmental agents in general, and microbiota, cigarette smoking, alcohol and coffee
consumption, socioeconomic status (SES), gender and sex hormones, vitamin D, organic
solvents, and vaccines in particular. Inclusion of the autoimmune ecology in disease etiology
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dolo (3.2-b) carbazole; GC, germinal center; GD, Graves’ disease; GO, Graves opthalmopathy; GSE, gluten-sensitive enteropathy; GST, 
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primary biliary cirrhosis; PBMC, peripheral blood mononuclear cells; PolyA, polyautoimmunity; PRR, pattern recognition receptors; 
PSC, primary sclerosing cholangitis; PTMs, post-translational modifications; RA, rheumatoid arthritis; RCTs, randomized controlled 
trials; RF, rheumatoid factor; RPL, recurrent pregnancy loss; RR, relative risk; SE, shared epitope; SES, socioeconomic status; SHM, 
somatic hypermutation; SIR, standardized incidence ratios; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythema-
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SMD, standardized mean difference; snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein; SPD, secondary progres-
sive disease; SS, Sjögren’s syndrome; SSc, systemic sclerosis; T1DM, type 1 diabetes mellitus; TAK1, TGFβ-activated kinase 1; TCDD, 
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FiGURe 1 | interaction of living and non-living components in the conformation of the biosystem. A system consist of regularly and interdependent 
components forming a unified whole. Systems containing living (i.e., biotic) and non-living (i.e., abiotic) components constitute biosystems, and range from genetic 
systems to ecosystems, all of them influencing their function and homeostasis. This multifactorial biosystem has a major effect in health, resulting into the concept of 
“the ecology of medical care.” Adapted from Ref. (4).
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legislation, and more new scientific studies (7). A framework 
for thinking about the organization of health care, medical 
education, and research has been provided that goes beyond the 
human ecology definition (8). This has resulted in a definition 
involving the relationships between people and their health 
care environment known as the “ecology of medical care” 
(4, 8, 9).
Over the years, a number of trans-National Institutes of 
Health (NIH) committees and NIH-supported workshops have 
examined the impact of the environment on autoimmune dis-
ease (AD) (10). In 2012, the National Institute of Environmental 
Health Sciences Expert Panel Workshop reviewed approaches 
for defining environmentally associated ADs in three contexts 
(11): (a) identifying the necessary and sufficient data to define 
environmental risk factors for ADs meeting current classifica-
tion criteria; (b) establishing the existence of and criteria for 
new environmentally associated ADs that do not meet cur-
rent disease classification criteria; and (c) identifying specific 
environmental agents that induce AD in individuals, typically 
in a clinical setting. They emphasized that additional efforts 
in all these areas are needed to achieve true consensus in this 
field and to define classification criteria that can distinguish 
environmentally associated AD cases from others with high 
sensitivity and specificity. Panel findings on studies of the role 
of environmental factors and development of ADs are shown in 
Table 1 (10).
For many perhaps most traits, the interaction with genes and 
environmental factors might be genetically programed or may 
be purely stochastic (12). However, recent evidence pointed out 
that environment, more than genetics, shapes immune system 
(13). As a corollary, just as multiple genetic risk factors influ-
ence the development of a given AD, multiple environmental 
factors are also required at different periods in life, or in a 
specific temporal sequence to affect the immune perturbations 
that result in AD (4). Thus, the autoimmune ecology (AE) refers 
to the analysis and study of interactions among individuals 
and their environment leading to a break of immune tolerance 
and, therefore, to the development of one or some ADs in such 
individual. It is also likely that diverse ADs may result by the 
interaction of multiple environmental factors. This supports 
the fact that AE is a crucial component of the autoimmune 
iNTRODUCTiON
Public health problems are increasingly complex, especially 
environmental and social threats arising from global changes, 
driven by rapid industrialization, population growth, over-
consumption of natural resources, and inappropriate use of 
technology (1). Understanding patterns of health and disease 
requires that public health attention be given to not only personal 
behaviors, biological traits, and specific risks but also the social 
and physical environmental characteristics that shape human 
experience (1).
Ecology originated in natural sciences (botany and zool-
ogy) during the late nineteenth century as the study of the 
interaction between plants and animals with the surrounding 
environment, involving interdisciplinary research of biology 
and earth sciences. Early in the twentieth century, social sci-
entists applied ecological principles to study human behavior 
and community organization (2). The word ecology is derived 
from the Greek oikos, meaning “household,” and logos, “study.” 
Thus, the environmental house includes all the organisms in it 
and all the functional processes that make the house habitable. 
Ecology is literally the study of “life at home” with the empha-
sis on “the totality or pattern of relations between organisms 
and their environment” (3). Perhaps the best way to delimit 
modern ecology is to consider the levels of organization seen as 
an ecological spectrum (Figure 1) and an extended ecological 
hierarchy (4).
At this basic level, human ecology can be thought of as the 
study of the environmental conditions in which human beings 
developed, and humans’ relationship with the ecosystems that 
support them. The same principles apply to the ecology of any 
species, but in the case of humans, their number on the planet, 
their presence in almost all terrestrial ecosystems, and their 
impact are largely the product of the human capacity for culture 
(5). The term “ecosphere” was sometimes used as an alternative 
for “biosphere,” thus considering the physical and biological 
aspects of the Earth as a unit, rather than biology alone (6).
Analysis of the environmental influence on chronic diseases 
has suffered continuous transformations. Concern about the 
environment’s effects on health has caught fire with joint health, 
urban-planning conferences and strategy sessions, pending 
TABLe 1 | Findings on human studies on the role of environmental factors and development of autoimmune diseases.
ePw is confident of the following ePw consider the following likely, 
but requiring confirmation
Broad themes to be pursued in future investigations
Chemicals
Crystalline silica (quartz) contributes to 
development of several ADs, including RA, 
SSc, SLE, and ANCA-related vasculitis
Solvents contribute to development 
of MS
There is insufficient evidence on the role of metals, including those associated 
with animal models of autoimmunity, e.g., mercury
Solvents contribute to development of SSc Smoking contributes to development 
of seronegative RA, MS, SLE, HT, 
GD, and CD
The identification of single causal agents within groups of exposures is needed 
(e.g., specific solvents or pesticides contributing to increased risk for the group)
Smoking contributes to development of 
ACPA-positive and RF-positive RA (with an 
interaction with the shared epitope genetic 
susceptibility factor)
Current smoking protects against 
development of UC
Studies are needed on plasticizers (e.g., phthalates and bisphenol A), some of 
which may be endocrine or immune disruptors, and have been associated with 
other immune-mediated diseases
There is insufficient evidence on the role of cosmetics in ADs
Physical factors
An inverse association exists between 
increased UV radiation exposure and risk of 
developing MS
Ionizing radiation contributes to 
development of HT and GD
There is insufficient evidence on a possible protective role of UV radiation on T1D
Prospective data are needed on sun exposure as a risk factor for SLE (prior to 
early clinical symptoms) and dermatomyositis
Biologic agents
Ingestion of gluten contributes to 
development of GSE
EBV infection contributes to MS 
development
Studies are needed on MS and vitamin D in racial/ethnic groups with darker 
skin (associated with UV-associated vitamin D deficiency), and examining 
dose-effects
Prospective data are needed on vitamin D and other ADs
Ingestion of certain lots of l-tryptophan 
contributes to development of eosinophilia 
myalgia syndrome
Early introduction of complex foods 
contributes to development of T1DM 
and GSE
Additional studies are needed on associations of food chemicals, dyes, or 
additives
Dietary intake of DEPAP and oleic anilide-
contaminated rapeseed oil contributes to 
development of toxic oil syndrome
Low dietary vitamin D intake 
and blood levels contribute to 
development of MS
Prospective studies are needed on nitrates/nitrosamines and T1DM
Modified from Ref. (10).
EPW, expert panel workshop; ADs, autoimmune diseases; RA, rheumatoid arthritis; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; ANCA, anti-neutrophil cytoplasmic 
antibody; ACPA, anticitrullinated protein antibody; RF, rheumatoid factor; MS, multiple sclerosis; HT, hashimoto’s thyroiditis; GD, graves’ disease; CrD, crohn’s disease; UC, 
ulcerative colitis; T1DM, type 1 diabetes mellitus; GSE, gluten-sensitive enteropathy; DEPAP, 1,2-di-oleyl ester; EBV, Epstein–Barr virus; UV, ultraviolet.
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tautology and reinforces the theory that ADs share several com-
mon mechanisms (14).
The AE is akin to exposome, that is all the exposures – internal 
(such as the microbiome, described elsewhere in this review) and 
external  –  across the lifespan, including physical environment 
(e.g., occupational hazards, exposure to industrial and household 
pollutants, water quality, climate, altitude, air pollution, and liv-
ing conditions and lifestyle and behavior such as diet, physical 
activity, cultural practices, use of addictive substances, and so 
on), interacting with hereditary factors (both genetics and epi-
genetics) to favor or protect against autoimmunity. However, the 
concept of AE as well as exposome extends beyond these factors 
to include social factors, such as socioeconomic status (SES), 
quality of housing, neighborhood, social relationships, access to 
services, and so on. (15–17).
To further contribute to the evidence about the nurture 
influence on ADs, herein we provide an overview of the AE. The 
focus will be on specific environmental factors and associated 
mechanisms that may be contributing to ADs. First is a review 
of the immunological and genetic bases of AE, then a review of 
the epidemiological bases of AE, which are mainly the influence 
of microbiota, lifestyle habits (i.e., alcohol, cigarette, and coffee), 
sex hormones, organic solvents (OSs), vaccines, SES on ADs, 
and environmental influence on polyautoimmunity (PolyA) 
(Figure 2).
iMMUNOLOGiCAL AND GeNeTiC BASeS 
OF AUTOiMMUNe eCOLOGY
Autoimmune disease is characterized by an immune response 
against self-antigens affecting about 5% of the population (18). 
Complex diseases have multifactorial origins, which imply that 
combinations of the many factors involved in autoimmunity 
produce varying and unique clinical pictures. Gene involvement 
in AD is inarguable with hundreds of risk loci identified for 
and shared between different diseases (19). Despite the genetic 
associations for each distinct AD, much of the heritability 
remains unaccounted for (20). The heritability of ADs is not 
fully understood. This establishes that the missing heritability 
probably reflects the fact that genes do not operate alone, but in 
the context of the environment leading to the gene–environment 
interplay (21, 22). That is, the degree of disease risk contributed 
by one factor will be influenced by the presence or absence of 
another (23).
Current classification criteria have primarily relied on epi-
demiological comparisons of disease incidence or prevalence 
in exposed and unexposed cohorts. However, other approaches 
have included immunological and animal model studies, which 
added considerable supporting evidence (24). A challenge in 
this field has been to clarify how much evidence is required to 
define a given exposure as a risk factor for ADs (25). Traditional 
TABLe 2 | environmental factors and mechanisms involved in 
autoreactivity.
environmental factor Main possible mechanisms
Infectious agents (bacteria/viruses) Innate immune activation via TLRs






T cell impairment (Th17/Treg cells)
Modification of self antigens
UV light Autoreactive B cells
Epigenetic changes (DNA methylation)
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TLRs, toll-like receptors; Th, T helper cells; 
UV, ultraviolet.
FiGURe 2 | environmental exposures associated with the development of autoimmune diseases (ADs). ADs are the result of the interaction between 
hereditary (i.e., genetic and epigenetic) and environmental factors over time. Autoimmune ecology is defined as the environmental exposures (i.e., cigarette smoking, 
coffee and alcohol intake, socioeconomic status, chemical agents, vaccines, incidental exposures, infectious agents, and microbiota) influencing the development of 
ADs and their outcome.
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epidemiological approaches were established for a number of 
associations initially outlined in 1965 (26).
The environmental risk factors associated with ADs are varied 
as are the underlying immune mechanisms that lead to these 
disorders (Table 2). The following sub-topics will be discussed: 
effects on innate immunity, such as toll-like receptor (TLR) 
activation by xenobiotics, adjuvant effects, and inflammatory 
responses; B-cell activation; direct effect impairing the immune 
function, such as T helper 17 (Th17) and T regulatory cells (Treg); 
post-translational modifications (PTMs) of self-antigens, and 
epigenetic modifications, mainly DNA methylation.
innate immunity
Toll-Like Receptor Activation, Adjuvant Effects, and 
Inflammatory Responses
Toll-like receptors are membrane bound proteins present in 
several immune cells, including B-lymphocytes, selective popula-
tions of T cells, dendritic cells (DCs), and macrophages as well as 
non-immune cells, such as epithelial cells and fibroblasts. TLRs 
recognize invading organisms bearing pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs) (27). PAMPs are conserved molecules 
derived from microorganisms, such as lipopolysaccharide (LPS), 
peptidoglycan, flagellin, and microbial nucleic acids, while most 
DAMPs are endogenous molecules released from dying host cell 
molecules upon cellular stress or tissue damage, such as oxida-
tive stress and heat shock proteins (28). Activation of TLRs by 
PAMPs or DAMPs can upregulate inflammatory cytokines and 
chemokines and engage intracellular signaling pathways to regu-
late the nature, magnitude, or duration of the host’s inflammatory 
response (29). TLR expression may rapidly change in presence 
TABLe 3 | effects of ligands of TLR2 or TLR4 on different cells in 
autoimmune diseases.
Disease Cells Ligands effects
RA Macrophage LPS Enhancing the production of 
proinflammatory cytokines
SLE PBMC LPS Dysregulation of cytokines and 
autoantibodies production
SSc DCs LPS Secretion of cytokines
SS Fibroblasts LPS Upregulation of the production 




Peptidoglycan/LPS Stimulating CD54 expression and 
IL-6 production
PBMC LPS/Zymosan A Inducing the production of IL-23/
IL-17
RA, rheumatoid arthritis; LPS, lipopolysaccharide; SLE, systemic lupus erythematosus; 
PBMC, peripheral blood mononuclear cells; SSc, systemic sclerosis; DCs, dendritic 
cells; SS, Sjögren’s syndrome. Adapted from Ref. (29).
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of cytokines, pathogens, and environmental factors (30). TLRs 
can be distinguished by their location; TLR1, TLR2, TLR4, TLR5, 
and TLR6 are present at the cell membrane, while TLR3, TLR7, 
TLR8, and TLR9 are in cell compartments, such as endosomes 
(31). There is constant interplay between the innate and adaptive 
arms of the immune system, and TLRs play a key role in this 
interaction.
The involvement of microbial PAMPs and endogenous ligands 
in autoimmunity through the activation of TLR and/or their 
increased expression acting in synergy with the formation of auto-
antigen–autoantibody immune complexes has been hypothesized 
(Table 3) (32). High mobility group box 1 (HMGB1) is a protein 
that acts as a DAMP when is located outside the cell, promoting 
the pathogenesis of autoimmune diseases. HMGB1 can interact 
with multiple receptors; in particular, the binding to TLR4 can 
lead to the activation of NF-κB and production of IL-6 and tumor 
necrosis factor (TNF)-α by macrophages (33). Furthermore, 
HMGB1 can bind to PAMPS, such as LPS, double-stranded RNA 
or DNA, and act through the partner’s receptor. This synergism 
could induce expression of mediators, such as the prostaglandins, 
to promote pain and inflammation in arthritis (34). The presence 
of PAMPs in tissues following infection has been associated with 
autoimmunity. These observations provide indirect evidence that 
PAMPs may promote autoimmune and chronic inflammatory 
conditions (35). There is a well-established link between infection 
and ADs in both clinical settings and animal models. This link has 
been attributed to either molecular mimicry between pathogen-
derived antigens and self-antigens or non-specific activation 
of innate immunity leading to a breakdown in immunological 
tolerance and development of self-antigen-specific T cell and 
antibody responses (35). Several studies in patients with multiple 
sclerosis (MS) have suggested that the disease may be triggered 
or exacerbated by infections with pathogens such as Chlamydia 
pneumoniae, human herpes virus 6, and Epstein–Barr virus (EBV) 
(36). Parvovirus B19 is considered one triggering factor for 
rheumatoid arthritis (RA) (37). The virus was detected by PCR 
in synovial biopsies from 75% of RA patients compared to 17% 
of patients with osteoarthritis and other arthritides. Furthermore, 
EBV DNA and RNA were detected in 34% of RA patients with the 
shared HLA-DR4 epitope compared with 10% of healthy indi-
viduals (38). Infection with Streptococcus pneumoniae 7 days after 
the induction of experimental autoimmune encephalomyelitis 
(EAE) exacerbates autoimmunity in wild type but not Tlr2−/− 
mice (39). This suggests that pathogens may exacerbate ADs 
via the activation of TLRs (Figure 3). Furthermore, PAMPs are 
present in the diseased tissues of patients with ADs. For example, 
peptidoglycans, which can act as ligands for nod-like receptors 
(NLRs) and TLR2, have been found in various cells and tissues, 
including in synovial tissue macrophages and DCs isolated from 
patients with RA (39, 40). Immunization of mice with myelin-
derived peptides in complete Freund’s adjuvant (CFA) induces 
active EAE. CFA contains killed Mycobacterium tuberculosis, and 
PAMPs from these bacteria activate innate immune responses, 
which, in turn, promote pathogenic autoreactive T cell responses. 
Marta et  al. showed that mice deficient in the adaptor protein 
MYD88 are resistant to EAE (41). This was associated with 
reduced IL-6 and IL-23 production by DCs and reduced IL-17 
and interferon (IFN)-γ production by T cells. This suggests that 
innate immune responses initiated through TLR or IL-1R signal-
ing are required for the induction of experimental autoimmunity. 
In the collagen-induced arthritis (CIA) model, which is induced 
by immunization with collagen and CFA, M. tuberculosis in CFA 
provides a source of PAMPs. Moreover, zymosan, a polysaccharide 
from the cell wall of Saccharomyces cerevisiae that binds TLR2, 
has been used to induce experimental arthritis in mice. Zymosan-
induced arthritis was found to be dependent on TLR2 activation 
as disease was substantially attenuated in Tlr2−/− mice (42). In 
addition, injection of immunostimulatory DNA sequences into 
joints of rats promoted development of adjuvant arthritis (43). 
This suggests that activation of TLR9 may also precipitate the 
innate immune responses that drive inflammation in joints (35).
Shoenfeld and Agmon-Levin coined the term “Autoimmune/
inflammatory Syndrome Induced by Adjuvants” (ASIA) (44). 
This syndrome is characterized by non-specific and specific 
manifestations of AD. An adjuvant is any substance that acceler-
ates, prolongs, or enhances antigen-specific immune response. It 
may stimulate the immune system and increase the response to a 
vaccine, without having any specific antigenic effect. Activation of 
the immune system by adjuvants, a desirable effect, could trigger 
manifestations of autoimmunity. The main substances associated 
with ASIA are squalene, aluminum hydroxide, silicone, mineral 
oil, guaiacol, and iodine gadital (45). Alum adjuvants are humoral 
immune potentiators in vaccine formulations. This property has 
been attributed to NLRP3 inflammasome activation, an intracel-
lular multiprotein complex that mediates caspase-1 cleavage of 
the inactive precursor of the proinflammatory cytokine IL-1β, 
leading to the release of its mature form. Inflammasome-
mediated cleavage of pro-IL-1β in vitro depends on signals that 
activate both TLR and nucleotide oligomerization domain-like 
receptors, such as NLRP3 (46, 47). The adjuvanticity of aluminum 
compounds is related to their association with uric acid. Alum 
appears to promote an inflammatory response that results in 
the release of uric acid from necrotic cells. Uric acid, in turn, is 
thought to increase the adjuvanticity of alum with an increase in 
IL-4 levels (45, 48). IL-4 drives the upregulation of monocytic 
FiGURe 3 | Pathogens-induced TLR signaling cascade in innate immune cells may exacerbate autoimmune diseases. Lipopolysaccharide (LPS) binds 
to TLR4 and peptidoglycans bind to TLR2, which initiates signaling by recruiting the adaptor proteins myeloid differentiation primary response protein 88 (MYD88), 
the TIR domain-containing adaptor protein (TIRAP), TIR domain-containing adaptor protein inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM). 
MYD88 associates with IL-1R-associated kinase 1 (IRAK1) and IRAK4 and recruits TNFR-associated factor 6 (TRAF6). This complex recruits TGFβ-activated kinase 
1 (TAK1), leading to phosphorylation of NF-κB inhibitor (IκB), activation of nuclear factor-κB (NF-κB), and consequent transcription of a range of genes coding for 
proinflammatory cytokines, including tumor necrosis factor (TNF), interleukin-6 (IL-6), pro-IL-1β, and pro-IL-18. In addition, TLR agonists activate the interferon 
regulatory factor (IRF) pathways, leading to the production of IL-12p35 and type I IFNs. TLR-induced activation of TAK1 also results in phosphorylation of 
mitogen-activated protein kinases (MAPKs), including p38 and extracellular signal-regulated kinase (ERK). Phosphorylation of ERK promotes the transcription of the 
gene encoding IL-23p19 and subsequent IL-23 synthesis. Phosphorylation of p38 activates cAMP response element-binding protein (CREB), leading to IL-10 
production. IL-1β activates its own receptor, which also signals via the same TLR pathway components to produce IL-1β. Adapted from Ref. (35).
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cell surface major histocompatibility complex (MHC) class II, 
a crucial component in developing innate immunity. Another 
danger signal hypothesized to enhance the adjuvanticity of alum 
is host cell DNA that is released from necrotic cells (49, 50). In 
susceptible individuals, aluminum-based adjuvants can induce 
AD although this is rare. ADs correlating with alum-based 
vaccinations encompass conditions, such as RA, type 1 diabetes 
mellitus (T1DM), MS, and systemic lupus erythematosus (SLE) 
(Figure 4) (45).
Subcutaneous injection of mineral oil has been shown to 
promote anti-chromatin/DNA autoantibody production even 
more efficiently than squalene or incomplete Freund adjuvant. 
This suggests that different types of autoantibodies could be 
produced in response to different hydrocarbons (51). Moreover, 
experimental models demonstrated that adjuvant oils induced 
T-cell-dependent polyarthritis (52).
Silicones are a family of synthetic polymers sharing a silicon 
oxygen chain with varying organic side groups. The link between 
silicone and immune-mediated diseases has been reported in the 
past and is one of the cornerstones of ASIA (53). Silicone is a 
component of breast implants. Although there is no clear associa-
tion between silicone and overt ADs (45), patients with severe 
immune-mediated reactions to implanted silicone devices were 
found to have increased immunoglobulin (IgG) in the surround-
ing tissue and higher levels of anti-silicone antibodies compared 
to asymptomatic implanted patients (54). An adjuvant action 
linking breast implants with development of autoantibodies 
has been hypothesized (55). Murine CIA model and the MRL 
FiGURe 4 | Mechanisms by which adjuvants trigger autoimmunity. Adjuvants (mainly alum) may function as delivery systems by generating depots that trap 
antigens at the injection site, providing slow release in order to continue the stimulation of the immune system, thus enhancing the antigen persistence and 
increasing recruitment and activation of dendritic cells (DC) (depot’s effect). Other adjuvants, essentially ligands for pattern recognition receptors (PRR), act by 
inducing the innate immunity by targeting the DC via toll-like receptors (TLRs). Adjuvants can direct support antigen presentation by the major histocompatibility 
complexes (MHC), inducing the differentiation of a naïve T cell in T helper 1 cells (Th1), T helper 2 cells (Th2), T regulatory cells (Treg), and T helper 17 cells (Th17). 
Adapted from Ref. (45).
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model of murine lupus showed that silicone was responsible for 
increased circulating levels of IL-2 in both models as well as the 
production of anti-DNA autoantibodies in the MRL model. Also, 
in the CIA model, long-term (12 months) silicone implantation 
resulted in an increased incidence and severity of arthritis (56, 57). 
Nonetheless, most of these reports indicate that silicone implants 
may cause a non-specific foreign body reaction, sometimes with 
autoantibodies.
Damage-associated molecular patterns or alarmins, which 
are released from dead or dying cells, can also stimulate innate 
immune responses that lead to autoimmunity. Ultraviolet (UV) 
radiation promotes necrotic cells that induce danger signals or 
DAMPs, thus activating TLR4. This activation may be respon-
sible for autoimmune responses (58). Furthermore, TLR4 can 
bind other endogenous ligands released from damaged cells, 
including several extracellular matrix components, such as 
hyaluronic acid oligosaccharides, fibronectin extra domain 
A, and fibrinogen, which are able to promote the synthesis of 
chemokines by macrophages. Also the abnormal internalization 
and transport of double-strain (ds) DNA fragments from necrotic 
cells into endosomes could induce autoimmune responses after 
binding to TLR3 (31). A characteristic of SLE is the presence of 
nuclear debris from the impaired clearance of apoptotic cells that 
become self-antigens able to bind B-cell receptors, induce TLR9 
expression, and activate both TLR9 and B-lymphocytes with the 
subsequent production of autoantibodies (59). Patients showing 
increased apoptosis causing the release of DNA and RNA can be 
sensed by TLR9 and TLR7, respectively (60). Human synovial 
membrane cultures from patients with RA were found to express 
TLR2 and TLR4 and to release endogenous TLR ligands that may 
contribute to destructive inflammation in these patients’ joints. 
Another component with a role in this disease is heterogene-
ous nuclear ribonucleoprotein (hnRNP), an RNA- and DNA-
binding complex that is a target of most nuclear antigen-specific 
B and T cells in systemic ADs, such as human RA and pristane-
induced arthritis in rats. Moreover, hnRNP triggers TLR7- and 
FiGURe 5 | Self nucleic acids recognition by TLRs in autoimmunity. Autoantibodies and autoreactive B-cell receptor BCRs, such as rheumatoid factor (RF) 
and anti-small nuclear ribonucleoprotein (snRNP) or anti-DNA antibodies mediate the access of self-nucleic acids to endolysosomal toll-like receptors (TLRs), 
leading to the production of type I interferon (IFN) from dendritic cells (DCs) and autoantibodies of corresponding specificities from B cells. The major snRNP antigen 
for anti-snRNP autoantibodies contains small nuclear RNA (snRNA), whereas the antigenic targets of anti-DNA autoantibodies are apoptotic or necrotic material 
containing DNA; accordingly, anti-RNP B cells are activated by TLR7 ligands, whereas anti-DNA or RF-producing B cells are activated by either TLR9 or TLR7 
ligands. Adapted from Ref. (62).
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TLR9-mediated activation of arthritogenic DCs, which activate 
pathogenic T cells (Figure 5) (61, 62).
B-Cell Activation
A major role of cells in the B-cell lineage is to generate antibody-
secreting plasma cells and memory B cells with an enhanced 
ability to respond to the specific initiating antigen. B cells 
increasingly emerge as part of a tightly regulated immune acti-
vation process with numerous intimate interactions with other 
immunocompetent cells that have been identified (63). Under 
normal resting conditions, B cells follow a tightly regulated life 
cycle with a large number of checkpoints at different stages (64). 
Dysfunctions at these tolerance checkpoints have been directly 
correlated with ADs in murine models (65, 66). In the bone mar-
row, B cells develop from stem cells through a series of precursor 
stages. During them, they rearrange their variable Ig genes to 
generate a wide range of unique antigen-binding specificities. B 
cells are critical for promoting ADs, including SLE (67–69), RA 
(70), T1DM (71), and MS (72), among others. A unique challenge 
to the maintenance of self-tolerance in the B-cell compartment 
is the BCR diversification within B cells that are recruited into 
T-dependent immune responses and ultimately enter the germi-
nal center (GC) reaction. Somatic hypermutation (SHM) of the 
IgG variable region genes of GC B cells results in the occasional 
generation of clones with increased affinity for foreign antigen, 
these cells being specifically perpetuated and subsequently dif-
ferentiating into the high-affinity plasma cells and memory B cells 
that provide long-term immunity. However, the random nature of 
the SHM process inevitably leads to the generation of self-reactive 
B cells in the GC that, unless somehow inactivated, have the 
potential to initiate autoantibody production. The fact that most 
pathogenic autoantibodies show the hallmarks of SHM and selec-
tion strongly suggests that failure to enforce self-tolerance in GCs 
may contribute to many autoimmune diseases. However, the self-
reactive GC B cells are normally kept in check and are only rarely 
allowed to differentiate into autoantibody-producing plasma cells 
(73). B cells facilitate autoimmunity by not only secreting autoan-
tibodies but also presenting auto-antigens to T cells and secreting 
proinflammatory cytokines (74, 75). Consequently, targeting B 
cells has become one of the most effective treatments for ADs 
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(76). Given the biology of B-lymphocytes, certain environmental 
agents with the following effects are expected to have the potential 
to enhance B-cell-mediated autoimmunity: (a) agents that induce 
activation or expansion of autoreactive B cells, such as those that 
cause enhanced transcription of pro-survival molecules like 
B-cell activating factor (BAFF) and relaxed negative selection 
against autoreactive lymphocytes; (b) agents that might induce 
secretion of pathogenic antibodies, such as those that promote 
necrosis or apoptosis that may lead to the inappropriate presenta-
tion of nuclear components to lymphocytes; and (c) agents that 
induce secretion of proinflammatory cytokines as endocrine 
disruptors (66).
Sex hormones, such as estrogen and prolactin, can differ-
entially activate autoreactive B-cell populations from different 
subsets, e.g., B2 cells, which are responsible for most of the 
high-affinity pathogenic antibody production and marginal zone 
autoreactive B cells. Therefore, a possible connection between 
B-cell-mediated and endocrine disruptors (i.e., environmental 
estrogens) has been proposed (77). dnMEK + CD2rtTA + (C57
BL/6 × SJL)F1 hybrid animals disclose an impaired extracellular 
signal-regulated kinase (ERK) resulting in increased IgG anti-
dsDNA antibody in female double transgenic mice. Moreover, 
male mice failed to make anti-dsDNA antibody even when 
both transgenes were present. Therefore, the failure in males to 
produce pathogenic antibody must result from sex hormones or 
other gender-specific differences (77). Sex hormones are thought 
to be responsible for the female predominance observed in SLE. 
The role of estrogen, which influences both humoral and cellular 
immunity, has been widely studied, particularly in the NZB/W 
F1 mouse model of spontaneous SLE (78). Autoantibody forma-
tion is accelerated by estradiol treatment of the females while 
tamoxifen, an estrogen blocker, ameliorates disease progression. 
CD40LG, an X chromosome gene, encodes a B-cell co-stimula-
tory molecule transiently expressed on the surface of activated 
T cells and is overexpressed on T cells from women but not men 
with SLE (79, 80). However, the CD40–CD40 ligand interac-
tion is crucial to the development of T-dependent immune 
responses. In mice, CD40L was shown to play an important role 
in promoting pathogenic IgG autoantibodies and kidney disease. 
ERK impairment has been found to result in overexpression of 
CD40L protein on CD4+ T  cells in female but not male mice, 
and the level of CD40L protein was twice the amount in females 
compared to males (79, 80). Estradiol has a central role in 
modulating antigen presentation, enhancing B-cell responses 
by increasing survival of autoreactive B cells and production 
of proinflammatory cytokines, such as IL-1, IL-6, and TNF-α. 
RA patients have higher levels of estradiol compared to healthy 
controls. Animals with CIA show decreased disease activity 
during pregnancy, and estrogen treatment in non-pregnant CIA 
mice leads to an increase in IgG1 antibodies, which may explain 
remission during pregnancy. In mice, estrogen has been shown 
to inhibit autoreactive B-cell apoptosis thus increasing their sur-
vival and contributing to disease severity mainly via engagement 
of estrogen receptor alpha (81).
Another environmental factor associated with increased risk of 
autoimmunity is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). 
Its effects on the immune system are primarily mediated through 
the aromatic hydrocarbon receptor (AhR). TCDD is released 
through incineration of waste, chlorine bleaching of paper, 
copper smelting, and wood burning. Nevertheless, nowadays 
the main source of TCDD is cigarette smoking. During prenatal 
development, TCDD-exposed mice displayed a clear enhanced 
autoimmune profile, including increased splenic CD5+ and fol-
licular B cells, increased autoantibody production, and increased 
autoimmune kidney lesions (82). Similar studies have been done 
on the effect of mercury and silver on autoimmunity in outbred 
mice, showing that both were able to induce B-cell activation and 
anti-nucleolar autoantibody production (83). These results are 
also supported by human studies showing that 40% of a human 
population chronically exposed to relatively high levels of mer-
cury (a gold-mining community) exhibit relatively high levels of 
anti-nucleolar autoantibody in their sera (84).
Chronic infection by B lymphotropic virus can prime B-cell 
activation, proliferation, and clonal expansion, leading to select 
more autoreactive B cells (85). Although the mechanisms by 
which these infection agents can induce autoimmunity are not 
fully understood, recent studies have shown an accelerated 
immune senescence due to chronic exposure to latent viruses. 
Latent cytomegalovirus (CMV) infection in the context of a 
chronic autoimmune response induces the recently described 
“chronic infection phenotype” in CD8+ T cells, which retains 
anti-infectious effector features while exhibiting autoreactive 
cytolytic potential (86).
T-Cell impairment
T-lymphocytes are the ones mainly responsible for maintaining 
self-tolerance, but, additionally, they actively participate in the 
cell and tissue damage mechanisms in autoimmune-mediated 
diseases. Th17 are a subset of T helper cells that participate in 
autoimmune conditions (87). Th17 differentiation is regulated 
by various cytokines and is closely related to the development of 
Treg. Th17 differentiation is induced by TGF-β and IL-6 in mice, 
and by IL-1β and IL-6 in humans (88). AhR activated by its ligand 
regulates Treg and Th17 cell development (89, 90). Moreover, 
AhR is essential for Th17 development through the interference 
of STAT1 activation (91). TCDD is the best-known ligand for 
AhR. Smokers have a higher risk of autoantibody-positive RA 
and a more severe disease course (92). The mechanisms by 
which smoking influences the development and course of RA 
are not fully understood (See Post-Translational Modification 
of Self-Antigens, Cigarette Smoking and Cigarette Smoking and 
PolyA), but the interaction of TCDD with AhR and the subse-
quently impaired function of Th17 and Treg could certainly be 
one. Moreover, nicotine, a major component of cigarette smoke, 
stimulates the α7-nicotine acetylcholine receptors that have 
immunomodulatory effects. These receptors are expressed on 
several immune cells, including monocytes, macrophages, T- 
and B-lymphocytes, DCs, and fibroblasts found in the inflamed 
synovial tissue of RA patients. In a rat adjuvant-induced arthritis 
(AA), a model of human RA, nicotine-pretreated arthritic rats 
displayed upregulation of IFN-γ as well as IL-17. Furthermore, 
DCs of nicotine-treated arthritic rats showed altered levels of 
IL-6, IL-12p35, and IL-23, which are critical for differentiating 
Th1 (IL-12p35) and Th17 (IL-6 and IL-23) cells (92).
10
Anaya et al. Autoimmune Ecology
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 139
Moreover, the IL-27 level was significantly lower in rats with 
more severe AA. Although the role of IL-27 in ADs is not fully 
clear, a lower level of IL-27 with the increased severity of AA by 
nicotine-pretreatment has been reported, assigning a regulatory 
role to this cytokine in AA (93). Cigarette smoking affects the 
cell-mediated and humoral immune responses by inducing the 
release of TNF-α, TNF-α receptors, IL-1, IL-6, IL-8, and granu-
locyte-macrophage colony-stimulating factor. However, smoking 
has also been associated with decreased IL-6 production through 
TLR2 and 9, decreased IL-10 production via TLR2 activation, and 
decreased IL-1β, IL-2, TNF-α, and IFN-γ production by mono-
nuclear cells (94). The release of intracellular antigens via tissue 
hypoxia or toxin-mediated cellular necrosis may precipitate an 
immune reaction in susceptible individuals. Smoking may also 
augment B-cell autoreactivity and stimulate the proliferation of 
peripheral T-lymphocytes (95).
In addition to IL-27 effects on rats with AA exposed to nicotine, 
other studies provide evidence of the implication of this cytokine 
in ADs. Toxoplasma gondii triggers the local expression of IL-27, 
dampening Th17 immunity and inducing chronic inflammation 
of the CNS (96). In vitro experiments showed that IL-27 sup-
pressed the differentiation of Th17 cells triggered by IL-6, TGF-β, 
and a STAT1-dependent pathway. Although this work clearly 
shows the direct effects of IL-27 on the Th17 subset in  vitro, 
IL-27 might also control the Th17 subset by indirect mechanisms 
in vivo. Indeed, IL-27 combined with TGF-β promotes the gen-
eration of suppressive T cells that produce IL-10. Whether these 
IL-10-secreting T cells can directly control the Th17 subset has 
not been formally proven as yet, but these observations indicate 
another possible level of regulation in the activity of IL-27 on 
the Th17 subset (96). Considering that exaggerated immune 
responses are also observed in IL-27 receptor-deficient mice 
infected with Leishmania donovani, Trypanosoma cruzi, or after 
helminth challenge, these studies provide a potential mechanism 
for controlling Th17-driven ADs by parasitic infections (97).
6-Formylindolo (3.2-b) carbazole (FICZ), a tryptophan 
photoproduct, is also a high-affinity ligand of AhR. Two differ-
ent high-affinity ligands for AhR activation, TCDD and FICZ, 
can play different roles in the differentiation of Th-cells and the 
pathogenesis of EAE. On the one hand, FICZ, a high-affinity 
“natural” AhR ligand, appears to increase only the Th17 popu-
lation, and therefore, worsen the severity of EAE (89). On the 
other hand and paradoxically, TCDD appears to expand only 
the Treg population and prevent EAE (90). Thus, depending on 
the ligand, AhR is capable of regulating both Treg and Th17 cell 
differentiation and either protect or worse ADs (98). A study in 
NFS/sld mice, a model of Sjögren’s syndrome (SS), showed that 
neonatal exposure to TCDD causes disruption of thymus selec-
tion. This increases the production of Th1 cytokines, such as IL-2 
and IFN-γ, from splenic CD4+ T cells and the autoantibodies 
relevant for SS in the sera of these mice (99). Though not directly 
demonstrated, changes in the thymic microenvironment in these 
TCDD-exposed animals could compromise Treg development 
facilitating autoantibody production (66).
Ultraviolet photoproducts of tryptophan, such as the high-
affinity ligand FICZ, could be synthesized in  vivo through 
exposure of human skin to UV light (89). UV light, in particular 
UV-A and UV-B, can induce disease flares in patients with SLE 
and trigger disease onset (100). Cellular damage in dermal cells 
from excessive exposure to UV-B ranges from proinflammatory 
apoptotic to necrotic cell death. The exposure of auto-antigens 
and release of proinflammatory cytokines by phagocytic cells 
could ignite the autoimmune response by directly stimulating 
autoreactive B cells or by providing lupus antigens to preexisting 
autoantibodies (101). Overall, necrotic cell death might be an 
ideal adjuvant for self-immunization in a genetically predisposed 
individual. Likewise, it is well established that lupus immune 
response is mostly antigen driven. Therefore, a constant supply of 
self-antigen(s) is needed, which it is likely provided by cell death. 
Additionally, apoptotic blebs and bodies are potential sources of 
lupus auto-antigens and targets for autoantibodies (100).
Silica exposure is well known to cause not only pulmonary 
fibrosis known as silicosis but also influence ADs, such as RA 
(i.e., Caplan’s syndrome), systemic sclerosis (SSc), SLE, and anti-
neutrophil cytoplasmic autoantibody (ANCA)-related vasculitis/
nephritis (102, 103). Chronic exposure to silica particles activates 
T-responder cells (Tresp) and Treg. The activated Tresp enter the 
peripheral CD4+ CD25+ fraction and activated Treg are lost earlier 
from this fraction due to apoptosis resulting in a reduced inhibi-
tory function. Chronically activated Tresp, in turn, may express 
Fas-mediated apoptosis inhibitory molecules, such as soluble Fas 
and so survive longer (104). These fractions may contain autore-
active clones and progress to subclinical manifestation of ADs. 
These cellular events also increase sIL-2R, reported in ADs as a 
marker of chronic activation of autoreactive T cells (103).
Post-Translational Modification  
of Self-Antigens
Most proteins consist of only 20 amino acids (aa), but when 
considering PTMs, a protein may consist of more than 140 
aa. PTMs are defined as covalent modifications occurring in a 
specific aa in a protein, and include acetylation, lipidation, cit-
rullination, phosphorylation, methylation, and glycosylation. A 
variety of chemical modifications may be present in a protein, 
and these modifications are time- and signal dependent. PTMs 
may arise either by enzymatic modification or spontaneously. 
Under physiological conditions, proteins are post-translationally 
modified to carry out a large number of cellular events, from cell 
signaling to DNA replication. However, an absence, deficiency, 
or excess of these PTMs can lead these “new” proteins to trigger 
autoimmunity (105).
The strongest association of an external environmental factor 
with RA observed so far is smoking, which contributes to local 
inflammation in the lungs (106). Inflammation, in turn, leads to 
apoptosis or necrosis of lung cells, calcium release, and activation 
of peptidylarginine deiminase (PAD) enzymes. PAD enzymes 
cause a specific PTM called citrullination. This occurs as part of 
normal intracellular homeostasis, but extracellular citrullination 
of proteins in tissues is characteristic of many if not all inflam-
matory conditions (107). Citrullination changes an arginine for a 
citrulline by deamination of the former. The basic charge conferred 
by arginine changes into a neutral site in the peptide, an event that 
may alter the tridimensional conformation of the protein (108). 
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These citrullinated proteins may subsequently trigger an immune 
response by binding to HLA-DRB1 shared epitope (SE) molecules 
(i.e., a 5-aa sequence motif in the third allelic hypervariable region 
of the HLA-DRβ chain associated with RA) on DCs leading to 
activation of pathogenic T and B cells, and ultimately promoting 
anticitrullinated protein autoantibody (ACPAs) formation. Several 
citrullinated proteins from fibrinogen, vimentin, α-enolase, 
and collagen type II constitute ACPA targets. Moreover, ACPA 
molecules contain additional N-linked glycans, and there is strong 
evidence that the introduction of N-linked glycosylation sites is 
a result of SHM and that the presence of these unusual sugars 
can modulate the binding to citrullinated antigens. This thought 
is sustained by the high rate of non-synonymous SHM detected 
in ACPA sequences (109). In particular, of the mammalian PADs 
characterized, PAD-4 may be associated with RA as they express 
in affected joints (110, 111). Polymorphisms and haplotypes at 
PADI4 gene influence the risk of developing RA (112). Although 
the association is slight, the functional effect is strong.
Klareskog et al. showed that smoking was strongly associated 
with increased risk of RA in those patients expressing ACPAs, a 
highly specific serologic RA marker (113). To further elucidate 
the relevance of this gene–environment interaction circle, the 
odds ratio (OR) of RA risk was 21 in those individuals bearing a 
double copy of the HLA-DRB1 SE allele compared to 6 in patients 
bearing only one copy (114). The presence of HLA-DRB1 SE is 
the strongest known genetic factor for susceptibility to RA. The 
possibility that other non-HLA genes may also interact with 
smoking to increase susceptibility to RA is supported by Mattey 
et al. study showing the association between smoking and disease 
severity in those patients bearing a polymorphism at the glu-
tathione S-transferase (GST) M1 locus (115). GST is important 
in detoxifying the xenobiotic atherogen generated by smoking. 
Smoking showed interaction with another major susceptibility 
gene in conferring risk of RA, the PTPN22 R620W allele (108).
Using lipstick and hair dye has been associated with SLE (101). 
Lipstick contains several chemical compounds, such as eosin and 
phthalates, which have been shown to induce photosensitivity 
and lupus flares, the production of anti-dsDNA antibodies, and 
progression of renal disease in NZB/W F1 mice, respectively. 
This is partly and potentially due to the breach of immunological 
tolerance by molecular mimicry (116). While the risk of induc-
ing lupus by hair dye containing aromatic amines is theoretically 
present, it is largely refuted by large observational studies in 
human lupus (25). Mechanistically, the potential lupus-inducing 
effect of aromatic amines is related to the fact that the amines 
are metabolized by acetylation, a process that shares a pathway 
similar to that of hydralazine (101). Thus, among slow acetyla-
tors, the accumulation of aromatic amines might induce SLE in 
genetically susceptible individuals.
epigenetic Modifications
Epigenetics is the study of changes in gene expression due to 
environmental influence without alterations in the underlying 
genetic sequence. Epigenetic modifications are generally classi-
fied into three main groups: cytosine genomic DNA methylation, 
modification of various side-chain positions of histone proteins, 
and non-coding RNA feedback (4).
Systemic lupus erythematosus is perhaps the best-studied 
AD with regard to epigenetic modification. Discordance noted 
in early monozygotic twin studies as well as racial and geo-
graphic variations in prevalence suggest a strong interaction 
between the environment and underlying genomic code in SLE 
(117). Environmental agents, such as cigarette smoke, mercury, 
silica, UV light, viral infections, and medications, have been 
demonstrated to induce oxidative stress. This, in turn, has been 
shown to inhibit and/or decrease the DNA methyltransferase 1 
(DNMT1) level, thus reducing DNA methylation in CD4+ T cells 
and enhancing autoimmunity (118). In fact, increasing evidence 
supports reactive oxygen species being not only proinflammatory 
byproducts of cellular responses to infectious or inflammatory 
stimuli but also fine-tuning regulators of autoimmune responses 
varying in time, location, and extent of reactive oxygen species 
production (119). DNA methylation refers to the methylation of 
cytosine bases occurring in CpG pairs to form deoxymethylcyto-
sine (dmC) and is a repressive modification. DNA methylation 
serves to not only help stabilize chromatin but also silence genes 
inappropriate to the function of any given cell, but for which the 
cell expresses transcription factors that might otherwise drive 
gene expression (118).
T cells from patients with active lupus have decreased total 
dmC content and decreased DNMT1 transcripts relative to 
patients with inactive disease and normal controls (120). During 
mitosis, the level of DNMT1 is regulated partly by the activated 
ERK signaling pathway. Patients with active lupus have impaired 
T cell ERK1/2 phosphorylation, and the degree of impairment is 
proportional to disease activity (121). The deficient ERK path-
way contribution to lupus has been further supported in mouse 
models by the finding that inhibiting T cell ERK pathway with a 
MEK inhibitor could induce autoreactivity in vitro and lupus-like 
autoimmunity in mice by promoting DNA hypomethylation and 
overexpression of methylation-sensitive genes (122). Decreases 
in ERK pathway signaling are concomitant with a diminished 
PKCδ phosphorylation. This direct link between PKCδ and 
ERK suggests that abnormalities in the PKC–ERK pathway 
from impaired PKCδ activation may contribute to human lupus 
through effects on DNA methylation in T and perhaps other cells 
(101, 123) (Figure 6).
Demethylated, autoreactive CD4+ T cells overstimulate 
antibody production by B cells and kill macrophages, thus 
releasing apoptotic nuclear material that stimulates lupus-like 
autoantibodies (124). Moreover, in CD4+ T cells, ITGAL (CD11a) 
is an integrin involved in both costimulation and cellular 
adhesion that, upon dimerization with CD18, forms leukocyte 
function-associated antigen 1. CD11a is overexpressed in SLE 
patients’ CD4+ T cells and correlates with disease activity (125). 
The upstream ITGAL promoter is demethylated in active lupus 
patients compared to controls, the degree of demethylation cor-
relating with disease activity. CD4+ T cells from patients with 
active lupus were also found to overexpress perforin, CD70, 
CD40L, and KIR due to demethylation in the respective promot-
ers (118). CD40L is encoded on the X chromosome, so T cells 
from women have one methylated and one unmethylated CD40L 
gene, while T cells from men have only one unmethylated gene 
(79). Furthermore, injecting experimentally demethylated CD4+ 
TABLe 4 | DNA methylation process in autoimmune diseases.
Disease DNA methylation
SLE T cells hypomethylation, IFN signature, hypomethylation of CD70, 
CD11a, CD40L, perforin
RA T cells and CD40 hypomethylation, synoviocytes hypermethylation
SSc T cells and fibroblasts hypomethylation, Wnt pathway genes 
hypermethylation
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; 
IFN, interferon.
FiGURe 6 | epigenetic autoimmune ecology pathways. Different environmental factors, such as cigarette smoke, chemicals, UV light, and viral infections cause 
oxidative stress, which lead to activation of the mammalian target of rapamycin (mTOR) pathway that can directly inhibit DNA methyltransferase 1 (DNMT1). 
Oxidative stress contributes in CD4+ T cells to site-specific decrease in phosphorylation of protein kinase C (PKC)δ T505, leading to functional loss of PKC and parallel 
reduction of extracellular signal-regulated kinase (ERK) phosphorylation. As a result of ERK activity, expression of DNMT1 is reduced, DNA hypomethylation occurs 
and CD4+ T cells become autoreactive. Adapted from Ref. (101).
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T cells into syngeneic mice causes anti-DNA antibodies and a 
lupus-like disease (118).
After exposure to UV-B irradiation, the growth arrest and DNA 
damage-induced 45a GADD45a levels are increased and accom-
panied by high levels of CD11a and CD70. The levels of GADD45a 
are inversely proportional to DNA methylation levels in human 
lupus CD4+ T cells. The transfection of GADD45a in vitro is suf-
ficient to increase expression of these methylation sensitive genes 
and induce autoreactivity (126). Furthermore, increases in oxida-
tive stress lead to activation of the mammalian target of rapamycin 
(mTOR) pathway, which can directly inhibit DNMT1 (127).
The importance of epigenetics in initiating and perpetuating 
autoimmunity is summarized in Table 4 (117). However, there is 
no clear evidence of the environmental agent involved in each of 
the epigenetic mechanisms known for these ADs. Despite great 
efforts and many studies, several environmental agents have been 
associated with a variety of ADs, but little is known regarding 
the specific cellular and molecular mechanisms involved for each 
causal environmental agent.
ePiDeMiOLOGiCAL BASeS OF 
AUTOiMMUNe eCOLOGY
Microbiota
There are different microorganisms that populate the gut known 
as intestinal microbiota. This process starts at the time of delivery 
and breastfeeding, and it plays an important role in the homeosta-
sis of the human body. Indeed, there are microorganisms in the 
microbiota that produce enzymes and molecules, which are not 
generated by human beings. Therefore, microbiota is important 
to normal metabolism because it is capable of degrading the dif-
ferent components in food (128, 129). However, microbiota may 
also influence other systems that do not seem to be related to the 
gut, such as the immune system. Moreover, it actively participates 
in the education of the immune system. For example, the devel-
opment of Th17 and Treg lymphocytes is highly dependent on the 
interactions of commensal bacteria with host cells in the intestine. 
That is why it is possible to establish a connection between micro-
biota and autoimmunity or inflammatory disorders (128–131).
Studies of germ-free (GF) animal models have demonstrated 
deficiencies in their immune system. It is noteworthy that micro-
biota is the first barrier against pathogenic microorganisms. They 
may produce molecules against the pathogens during infection 
because they occupy the same niche, thus competing for the same 
place. GF mice show deficiencies in T-lymphocyte differentiation 
within the lamina propria in the presence of IgA in mucosal layers 
and alterations in the homeostasis of Th populations (Th1, Th17, 
and Treg). Furthermore, GF mice spleens show few GCs that 
indicates abnormal development and maturation of cells in the 
lymphoid follicles (128–130). As a result, the cytokine production 
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and the normal maturation process of immune cells are greatly 
affected (129).
Microbiota varies from one individual to another and even 
in the same individual over the course of his life. However, there 
are many factors that influence the composition of microbiota. 
Initially, newborns are sterile, and their microbiota depends 
on maternal transfer at the time of delivery, breastfeeding, and 
skin contact with the mother. For example, there are differences 
between children that were born by natural delivery and cesarean 
section, and also between children that were breastfed and those 
fed with formula. The latter group in both cases is colonized by 
potential pathogens and, in contrast with first group, they pre-
sent a lack of beneficial commensal microorganisms (129, 132). 
Nevertheless, their own genetic background plays an important 
role in determining the microbiota before contact with the 
mother’s microbiota. For example, animal models with gene 
alterations related to the innate immune system have problems 
in the signaling pathways associated with pattern recognition 
receptor (PRR) recognition (e.g., TLRs and NODs). These mod-
els also have important differences in the pattern of microbiota 
microorganisms compared to wild-type animals (128–130).
In addition, the evolution of medical treatment, stress, and 
quality of life influence microbiota development. For example, 
antibiotics are the treatment for infectious diseases, but their use 
is linked with the loss of beneficial microorganisms. Moreover, 
they alter the microbiota ecology because they affect the equilib-
rium between different bacterial species in the gut, which allows 
opportunistic pathogens to attack the body (129). Finally, diet 
plays a central role in the homeostasis of the microbiota because 
it defines which microorganisms can survive in the gut due to dif-
ferences in the preferences of microorganisms for energy sources. 
Thus, diet composition is extremely important in microbiota 
maintenance. Components from plants are the energy source 
for beneficial microbes and promote their growth over other 
microbes. It has been suggested that differences in the modern 
western diet could be causing the rapid increase in diseases, such 
as asthma (129, 133). For example, one study shows how a switch-
ing from a low fat, vegetable-rich diet to a high fat, high sugar diet 
could alter the microbiota within 1 day (129, 134).
Altogether, there is a lot of variability in microbiota between 
individuals, and it also varies based on the anatomic area of the 
human body (135, 136). Fluctuations in microbiota population 
have been described in patients with ADs (128). In addition, 
most of the studies have established a relationship between the 
microbiota inhabiting the gut and its influence on health. Usually, 
microorganisms that live in the gut are not pathogenic under 
healthy conditions, and they have a positive effect on the host 
(130). Nevertheless, some commensal bacteria may drive the 
preferential development of Treg, while others promote Th17 
response and inflammation. These bacteria favor the production of 
regulatory molecules and cytokines, e.g., Foxp3 and IL-10, which 
characterize the regulatory cells, Treg in particular. Specifically, 
species such as Bacteroides fragilis and the genus Lactobacillus 
and Bififobacterium greatly promote the presence of Treg in 
the gut. By contrast, a pathogenic phenotype characterized by 
Th17 response and proinflammatory cytokines is promoted by 
segmented filamentous bacteria, such as Firmicutes (Figure 7). 
Moreover, it has been demonstrated that this kind of bacteria is 
able to induce the production of IgA in the small intestine. Th17 
response certainly has its own positive role in the case of infection 
control, but it is also critical in the development of inflammatory 
and autoimmune diseases (128–130, 135).
Any change in microbiota could induce a dysbiosis and a 
pathological event. At present, the use of antibiotics, such as 
ampicillin, gentamicin, and vancomycin, may affect the balance 
toward bacteria that stimulate the Th17 response. At the same 
time, the consumption of a diet rich in sugar and fat favors a rise in 
the population of Firmicutes and a reduction in the Bacteroidetes 
(128, 129, 135). Finally, the influence of microbiota on the immune 
balance does not depend exclusively on the presence of the micro-
organisms, but it also depends on molecules that are produced 
by microbes and can stimulate specific pathways associated with 
immune tolerance (129). An example is the anti-inflammatory 
effect of the short-chain fatty acids, e.g., acetate, propionate, and 
butyrate. These fatty acids can bind to the G-protein-coupled 
receptor (GPR43 and GPR120) that is expressed in most of 
the innate immune system cells and, thus, produce an anti-
inflammatory action (129). The anti-inflammatory events induce 
the maintenance of the epithelial barrier, regulate apoptosis, 
diminish oxidative DNA damages, and regulate cytokine produc-
tion, phagocytosis, and neutrophil recruitment. At the same time, 
the peptidoglycan and the polysaccharide A teach the immune 
system to recognize potential pathogenic bacteria, and they also 
help in the correct development of balanced T-cell response in 
the gut. This balanced response promotes cell–cell interaction by 
modification of protein expression in immune cells (129).
Different studies have shown the microbiota as a changing 
ecosystem that has many factors in the model (136). Most of these 
studies try to determine what these microorganisms are and how 
they vary over time. However, the study of these microorganisms 
represents a challenge in terms of methodology because their 
identification was done by culture, and most of them cannot be 
grown in laboratory conditions. Therefore, most of them are now 
being studied with the help of DNA high-throughput analysis. 
Indeed, analysis of the entire DNA allows the study of all the 
organisms present in a sample (137, 138).
Due to the current metagenomic results (i.e., the study of the 
genomes in a specific environment) (139, 140), the analysis of 
the microbiota is moving forward and new OMICS have been 
identified. However, the real involvement in host systems does 
not depend exclusively on the presence of a specific microbiome. 
For instance, metagenomics would be just a representation of 
what these microorganisms are. Moreover, molecules produced 
by microorganisms can interact with the host at different levels 
leading to diverse outcomes. In consequence, it is important 
to study gene expression (metatranscriptomics), proteins 
(metaproteomics), and metabolites (metametabolomics) from 
a microbiome. These analyses, including possible interactions 
within the host system and under certain conditions can settle 
the real mechanisms by which specific microorganisms (present 
in a particular microbiome) may influence the host system and, 
thus, lead to complex disease modulation, such as ADs (138).
There are different strategies for analyzing data. Currently, the 
sequencing of the 16S rRNA gene has made it possible to describe 
FiGURe 7 | Factors influencing gut microbiota. A balancing microbiota in symbiosis influences the equilibrium between T regulatory cells (Treg) and effector  
T cells (Th1, Th17). As a consequence, the gut can respond to an infection but this also leads to the permanence of microbiota and favors the host. By contrast, if 
the environment induces the rupture of the equilibrium, it induces a state of dysbiosis. Hence, the percentage of anti- inflammtory microorganisms (e.g., 
Bacteroidetes and Lactobacillus) may be lower than proinflammatory microorganisms (e.g., Firmicutes). Eventually, this may lead to an inflammatory profile that 
favors the development of autoimmunity. Adapted from Ref. (129, 130).
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prokaryote taxonomic diversity. This gene has been used for this 
type of analysis for three main reasons. Primarily, it is present 
in every population member due to its essential role in protein 
translation in all prokaryotes. Second, 16S rRNA always and only 
differs between individuals with different genomes. Third, it is 
considered an evolution marker between species because its func-
tion is extremely important, so any change in its sequence can be 
potentially lethal. Therefore, the 16S rRNA sequence analysis brings 
us to the construction of operational taxonomic units (OTUs) 
based on the percentage of similarity between sequences. Then, 
comparison between multiple databases leads to the identification 
of species within a sample. Finally, the population becomes a 16S 
rRNA sequence collection where the number of unique sequences 
represents the number of microorganisms (136).
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Furthermore, high-throughput DNA sequencing technologies 
have recently become very useful for metagenomic analysis (i.e., 
pyrosequenciation). Thus, different strategies for different types 
of genome assembly and annotation within a sample are used 
to ensure an accurate description (141). In addition, potential 
proteins encoded in each genome can be analyzed based on DNA 
sequence. As a result, it is possible to assign a role or function for 
a specific microorganism within the microbiome based only on 
their genome capabilities (137).
The relationships between infection and ADs and its main 
mechanisms have been outlined (i.e., host–guest interaction). 
Nonetheless, most of the interactions and mechanisms that 
influence this relationship are still unknown. Microorganisms 
may alter and deregulate gene transcription, translation, and 
human metabolic processes. This means that the effect induced 
on the host by a microorganism is not caused by the presence of 
the microorganism itself but also by the metabolic and genetic 
polymorphism of the microorganism. In particular, intracellular 
pathogens may have a direct influence on gene regulation and 
protein expression inside host cells (131, 132, 142).
In the last few years, most of the large cohort studies have 
evaluated genetic factors that may predispose to ADs. In addition, 
expression and proteomic analysis have also been done, and most 
of them have tried to find a way to establish predictor genetic 
factors for the diseases. However, these studies do not take into 
consideration the DNA, RNA, and proteins from microorganisms 
that could be considered potential “contamination,” and which 
should be considered a source of information that would help 
complete the overall picture of molecular interactions between 
infection and ADs and make it understandable (132, 143, 144).
Last but not least, familial autoimmunity and polyautoimmun-
ity should be incorporated into the study of infection and ADs 
(145, 146). ADs may be associated with a specific family group 
exposed to a particular environment. Within this environment, 
family members will be in contact with the same microorganism, 
and they will develop the same microbiota. As a new common 
mechanism for ADs, microbiota can be “inherited” from parent 
to child, and it can also be shared among siblings (135).
Lifestyle Habits and Autoimmunity
Cigarette Smoking
Cigarette smoking has been widely associated with cardiovascular 
disease (CVD), pulmonary disease, cancer, and increased overall 
mortality. The association with ADs has also been extensively 
studied and confirmed based on the direct tissue damage and 
inflammatory response to tobacco (92).
For RA, a clear causal relationship between tobacco and 
RA risk was established in 1987 even though previous studies 
had already recognized its association with RA comorbidities 
(147–149). Since then, many case-control and cohort studies 
have evaluated and confirmed this relationship (150–154). 
Additionally, cigarette smoking was found to increase the risk 
of seropositive RA (rheumatoid factor (RF) and/or ACPA) both 
in Caucasians and Latin Americans (155–157). Tobacco also 
influences the phenotype or clinical expression of disease, and is 
related to earlier onset of disease (158, 159). For instance, smokers 
have a worse outcome with greater disability and disease activity, 
and have usually taken significantly more disease-modifying 
antirheumatic drugs (DMARDs) combinations or biologics than 
non-smokers (155, 158, 160).
A dose–response association between cigarette smoking and 
RA development was also confirmed by a recently published 
meta-analysis. Three prospective cohort studies and seven case-
control studies, including 181,100 subjects and 4,552 RA cases 
were considered for analysis. Compared to non-smokers, patients 
who smoked 1–10 pack-years presented an increased risk for RA 
[relative risk (RR): 1.26, 95% CI: 1.14–1.39]. Those who smoked 
more than 20 pack-years had an even higher risk, with a RR of 
1.94 (95% CI: 1.65–2.27) and, for those with more than 40 pack-
years, the RR was 2.07 (95% CI: 1.15–3.73) (161).
A systematic review and meta-analysis on the influence of ciga-
rette smoking on disease activity and joint erosions in RA showed 
a negative association between smoking and EULAR response 
(OR: 0.72, 95% CI: 0.57–0.91; p = 0.005) and DAS28 remission 
(OR: 0.78, 95% CI: 0.63–0.96, p = 0.023). DAS28 was significantly 
higher in current smokers [mean difference (MD): 0.29, 95% CI: 
0.12–0.44, p < 0.001] as well as erosive score [standardized mean 
difference (SMD): 0.38, 95% CI: 0.04–0.72, p = 0.028]. Data were 
ambiguous for erosion progression during follow-up (OR: 0.93, 
95% CI: 0.72–1.2; p = 0.59) (162).
As for RA, cigarette smoking is also associated with increased 
risk of SLE. A meta-analysis showed that for current smok-
ers, compared to non-smokers, the odds for developing SLE 
were significantly higher (OR: 1.50, 95% CI: 1.09–2.08) (163). 
Additionally, current smokers with SLE are more likely to have 
anti-DNA antibodies than non-smokers (164). This last find-
ing is related to the evidence of increased disease activity (i.e., 
SLEDAI score) observed in SLE patients that are current smokers 
compared to non-smokers (165). Furthermore, cigarette smoking 
(i.e., ever smoking) has been associated with CVD in patients with 
SLE (166). When smoking and coffee factors were combined, the 
association with cardiovascular risk in SLE remained statistically 
significant [adjusted odds ratio (AOR): 1.82, 95% CI: 1.05–3.13, 
p = 0,03].
Environmental exposure (i.e., ever smoke, coffee consump-
tion, silicone implants, organic solvents, hair dye, and pesticide 
exposure) influences the risk of developing lupus nephritis (LN) 
in a Latin American population when examined by latent variable 
analysis using the two-parameter logistic item response theory 
model (167).
Exposure to tobacco smoke has also been associated with a 
higher incidence of other AD, such as MS. Cigarette smoking 
increases the risk of progressive disease from the moment of diag-
nosis. Also, current smokers progress from relapsing-remitting 
disease to secondary progressive disease faster than non-smokers 
(168, 169). Regarding autoimmune thyroid disease (AITD), a 
meta-analysis was done including eight observational studies that 
showed an association between Graves’ disease (GD) and current 
and ever-smoking status, with an OR of 3.02 (95% CI: 2.09–5.22) 
and 1.9 (95% CI: 1.42–2.55), respectively. An association between 
Hashimoto thyroiditis and tobacco was also found (OR: 1.92, 95% 
CI: 1.25–2.93) (170).
Furthermore, a strong association has been found between 
primary biliary cirrhosis (PBC) and smoking in three large 
TABLe 5 | Association between smoking status and autoimmune disease onset and evolution.
Disease Disease onset evolution Reference
ever Current Past ever Current Past






NA EULAR response POR 
0.72 (0.57–0.91)
DAS28 remission POR 
0.78 (0.63–0.96)
(161, 175)














Mean SLEDAI 9.64 
(7.61–11.67)
(163, 164)
MS AOR 1.32  
(1.10–1.60)
NA NA NA Progression to SPD HR 
2.5 (1.42–4.41)
NA (168, 169)






Development of GO 
POR 2.53 (1.70–3.77)
Development of GO 
POR 2.18 (1.51–3.14)
NA (170)
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; MS, multiple sclerosis; AITD, autoimmune thyroid disease; POR, pooled odds ratio; AOR, adjusted ODDs ratio; HR, 
Hazard ratio; NA, not available; EULAR, European League Against Rheumatism; DAS28, disease activity score-28; SLEDAI, systemic lupus erythematosus disease activity index; 
SPD, secondary progressive disease; GO, Graves opthalmopathy. All results in parentheses correspond to 95%CI.
aResults in men.
bResults in women.
Adapted with author’s permission from Ref. (4).
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case-control studies (171–173). In addition, cigarette smoke accel-
erates the progression of PBC (174), all of these pieces of evidence 
raising the issue of the influence of tobacco on Th1 response.
In conclusion, cigarette smoking is one of the best-recognized 
environmental factors associated with AD. Different outcomes 
have been related to this association: disease onset, progression, 
activity, and treatment response. Relevant evidence available is 
summarized in Table 5 (175).
Alcohol Consumption
Multiple studies have evaluated the relationship between alcohol 
consumption and the risk of ADs, especially regarding RA and 
SLE. Most of the available evidence has come from case-control 
studies, which show a reduced risk for both RA and SLE with 
a low-to-moderate alcohol intake (157, 176–180). By contrast, 
some case-control studies (181, 182) and a prospective cohort 
analysis (183) have shown no association between alcohol and 
autoimmunity.
Since the evaluation of lifestyle impact on disease by case-
control studies may present a recall bias, two prospective studies 
have been done on the evaluation of alcohol and RA. The first 
was subdivided into two large cohorts, the Nurses’ Health Study 
NHS and NHSII, showing 580 incident cases of RA in 1.9 million 
person-years from 1980 and 2008 and 323 incident cases of RA 
in 1.78 million person-years from 1989 to 2009. In these cohorts, 
the pooled adjusted hazard ratio (HR) for moderate alcohol use in 
seropositive RA was 0.69 (95% CI: 0.50–0.95) indicating a protec-
tive effect of alcohol consumption (184). In the second cohort 
study, 34,141 women were followed from 2003 to 2009 with 197 
incident cases of RA identified. Here, there was a statistically 
significant 37% reduced risk of RA among women who drank 
more than four glasses of alcohol per week, compared to those 
who drank less than one glass per week or non-drinkers (RR: 
0.63, 95% CI: 0.42–0.96) (185).
Additionally, two meta-analyses for RA and one meta-analysis 
for SLE have been done to evaluate risk associated with alcohol 
intake. For RA, one of the meta-analyses included nine studies 
(six case-control and three cohorts) comparing drinkers vs. non-
drinkers and finding an adjusted OR of 0.78 (95% CI: 0.63–0.96). 
The protective effect was stronger in seropositive RA (0.52, 95% 
CI: 0.36–0.76) than that in seronegative RA (0.74, 95% CI: 0.53–
1.05). Subgroup analysis by study design identified a significant 
association in case-controls but not in cohort studies (186). The 
second study considered eight prospective studies that contained 
195,029 participants and 1,878 RA cases. Dose–response meta-
analysis of the study data revealed that, compared to no-alcohol 
consumption, the adjusted RR was 0.93 (95% CI: 0.88–0.98) for 
3  g/day of alcohol consumption, 0.86 (95% CI: 0.76–0.97) for 
9  g/day, 0.88 (95% CI: 0.78–0.99) for 12  g/day, 0.91 (95% CI: 
0.81–1.03) for 15 g/day, and 1.28 (95% CI: 0.94–1.73) for 30 g/
day, indicating an inverse association between low-to-moderate 
alcohol intake and RA risk (187). For SLE, six case-control studies 
and one cohort study were included for analysis, and an overall 
significantly protective effect was found when considering SLE 
patients treated for <10 years (OR: 0.72, 95% CI: 0.55–0.95) (188).
Despite the evidence showing the protective effect of alcohol 
in two common ADs, it should be remembered that the evidence 
for the harmful effects of alcohol remains stronger than its ben-
efits (181). Thus, no promotion of alcohol intake to prevent ADs 
is recommended.
Coffee Consumption
A few studies have been done to examine the effect of coffee on the 
risk of ADs. A meta-analysis evaluated the association between 
coffee or tea intake and the risk of RA. This analysis included five 
studies (three cohorts and two case-control) involving 1,279 cases 
of RA and 133,622 controls. The final effect size showed a sig-
nificant association between total coffee intake and RA incidence 
(RR: 2.426, 95% CI: 1.060–5.554, p = 0.036). When stratified by 
seropositivity, a significant association between coffee consump-
tion and seropositive RA incidence was found (RR: 1.329, 95% CI: 
1.162–1.522), but no association in seronegative RA (RR: 1.093, 
95% CI: 0.884–1.35, p = 0.411) (189). Another study evaluated 
the relationship between coffee intake and methotrexate (MTX) 
FiGURe 8 | Socioeconomic status (SeS) and autoimmune diseases (ADs). Some of the main findings associated with autoimmune diseases related to high or 
low socioeconomic position are shown.
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efficacy in RA, measured by DAS28 score, Multi-Dimensional 
Health Assessment Questionnaire (MDHAQ) score, and dura-
tion of morning stiffness with no statistical difference between 
groups (190).
Concerning SLE, a cross-sectional study was done on 310 
Colombian patients to evaluate the risk factors associated 
with the appearance of CVD as the leading cause of mortality. 
The estimated AOR for coffee consumption was 1.75 (95% CI: 
1.01–3.04, p = 0.043). Additionally, to isolate the interaction of 
smoking and coffee consumption, two regression models were 
made, showing an independent effect of coffee and tobacco on 
CVD. Their interaction remained significant (AOR: 1.82, 95% CI: 
1.05–3.13, p = 0.03), thus demonstrating their synergism (166).
The association between coffee consumption and ADs has also 
been evaluated in latent autoimmune diabetes in adults with no 
statistically significant association (191). However, other studies 
have demonstrated the opposite relationship between maternal 
coffee consumption and developing advanced β-cell autoimmun-
ity in the offspring (highest quarter vs. lowest HR: 0.62, 95% CI: 
0.40–0.97, p = 0.04) (192).
Two studies have evaluated coffee consumption, primary scle-
rosing cholangitis (PSC), and PBC. The first study included data 
from 480 patients with PSC, 606 with PBC, and 564 healthy vol-
unteers. Interestingly, 24% of patients with PSC had never drunk 
coffee compared to 16% of controls (p <  0.05), and only 67% 
were current drinkers compared to 77% of controls (p < 0.05). 
Furthermore, patients with PSC consumed fewer lifetime cups 
per month (45 vs. 47 for controls, p < 0.05) and spent a smaller 
percentage of their lifetime drinking coffee (46.6 vs. 66.7% for 
controls, p < 0.05). Moreover, among PSC patients with concur-
rent ulcerative colitis, coffee protected against proctocolectomy 
(HR: 0.34, p < 0.001). By contrast, patients with PBC and controls 
did not differ in coffee consumption parameters (193). The second 
study included 240 patients with PSC and 245 contro l subjects. 
The results suggested a protective effect of both cigarette smoking 
and coffee consumption at the age of 18 with the development of 
PSC (p < 0.05 and p = 0.048, respectively) (194).
Socioeconomic Status and Autoimmunity
The social environment includes social, political, economic, and 
cultural norms and values that result in an unequal distribution 
of resources that can negatively impact health. Many studies have 
evaluated the association between SES and chronic diseases, 
showing greater morbidity and mortality in people with lower 
socioeconomic position (195).
SES contributes to the observed difference in the prevalence 
of immunological disorders based on time and geographical 
distribution (Figure  8). As better public health measures have 
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been taken since the industrial revolution, there has been a major 
decline in infectious diseases with a simultaneous increase of 
ADs. This has been cataloged as the hygiene hypothesis (196). 
According to this theory, social and environmental exposures 
have a direct impact on immune tolerance and response, sup-
porting the association between SES and AD development.
In RA, different studies have reported a reduced risk as the 
educational and income level rise (197–199). Furthermore, 
a correlation was found between 11  years of education or less 
with a two-fold increase in poor prognosis (200). For instance, 
the lower the patient’s educational level, the greater the chance of 
mortality and the lower their functional capacity (201). In terms 
of self-assessment, health quality is usually low in patients with 
RA who are older, female, less educated, obese, unemployed, and 
less affluent than other groups (202, 203). Many RA patients tend 
to be unable to work due to their low functional capacity. Thus, 
they become dependent on the state for health services and social 
welfare support (204).
A recently published study was done on 1,209 RA patients to 
examine the association between SES and DMARDs treatment 
delays, disease activity, joint damage, and disability. Disease 
activity was determined by DAS28, joint damage was determined 
from hand radiographs by Sharp score, and physical disability 
was determined by MDHAQ. On average, patients with lower 
SES waited 8.5 ± 10.2 years after onset of RA symptoms to begin 
DMARD treatment compared to those in the middle and upper 
SES who waited 6.1 ± 7.9 years (p = 0.002) and 6.1 ± 8.6 years 
(p =  0.009), respectively. Moreover, patients with the greatest 
DMARD lag showed greater DAS28, Sharp, and MDHAQ scores 
(p < 0.001) (205).
In terms of mortality, a retrospective cohort study was done on 
the Taiwanese population to evaluate the association of individual 
SES/neighborhood SES, and mortality rates in 23,900 RA patients 
from 2004 to 2008. Analysis revealed that 5-year mortality rates 
were worse among RA patients with a low individual SES com-
pared to those with a high SES (p < 0.001). Additionally, patients 
with low SES in disadvantaged neighborhoods had the highest 
risk of mortality (HR: 1.64, 95% CI: 1.26–2.13, p < 0.001) (206).
For SLE, there is a tendency to earlier onset and worse out-
comes in people of Hispanic, Asian, or African ancestry compared 
to Caucasians. This may be partly related to overall poor SES, 
including less structured families, fewer years of formal educa-
tion, occupational status, household income, higher  poverty, and 
inadequate health insurance (199). The costs of SLE can be differ-
ent depending on the health care system. The impact of indirect 
costs is influenced by poor physical and mental health, low social 
support, low educational level, unemployment, and high disease 
activity (199, 207). Moreover, patients with elevated mortality 
and incidence of end-stage renal disease reported greater levels 
of poverty (199).
A cross-sectional study done on Mexican SLE patients 
evaluated the relationship between SES and organ damage. Lupus 
activity and organ damage were measured using the SLEDAI and 
Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology (SLICC/ACR) scale. The analysis 
included 143 SLE female patients, of which 42.7% presented 
organ damage. Patients with organ damage had lower monthly 
household incomes and were more frequently unemployed. Low 
monthly income was not associated with lupus activity or self-
reported altered health status (208).
The relationship between low SES and cardiovascular risk 
factors in SLE has also been evaluated. A longitudinal cohort 
study included 1,752 SLE patients. Regression analyses stratified 
by ethnicity and low income were strongly associated with most 
traditional cardiovascular risk factors in Caucasians, but only 
with smoking and diabetes in African Americans. In Caucasians, 
low income increased the risk of both myocardial infarction (OR: 
3.24, 95% CI: 1.41–7.45, p = 0.006) and stroke (OR: 2.85, 95% CI: 
1.56–5.21, p = 0.001); in African Americans, these relationships 
were not seen. Moreover, low education was associated with 
smoking in both ethnic groups (209).
For MS, African Americans have been reported to start at a 
younger age, in comparison to Caucasians or Hispanics. Access 
to neurology consultation and rehabilitation services was deter-
mined by health insurance, poverty, and living in rural areas. 
Additionally, important improvements in quality of life related 
to educational level and employment status in MS patients were 
identified (210, 211).
In conclusion, SES has a major impact on health as it affects 
biological functions. In general, low SES has been associated with 
worse outcomes and prognosis in ADs. The biological relevance 
of SES relies on ancestry and environmental exposure (199).
Sex Hormones, Gender, and Autoimmunity
Differences in AD manifestations by gender involve immu-
nomodulation by sex hormones, non-hormonal factors encoded 
by genes on the X and Y chromosomes, and immunological phe-
nomena unique to pregnancy (212). Over 75% of patients with 
ADs are estimated to be women, and hormones are important 
in regulating the onset, severity, and progression of the disease 
(213). In fact, AD is considered the fourth leading cause of 
 disability for women (214).
Many studies have postulated that oral contraceptive (OC) 
exposure exacerbates SLE activity, but the evidence has been con-
troversial. Two randomized controlled trials (RCTs) addressed 
this issue. The first RCT was single-blinded, and included 162 
women with SLE who were randomly assigned to a combined 
OC (30 μg ethinyl estradiol), a non-eluting intrauterine device, 
or a progestin-only pill for 12 months. There was no statistical 
difference in the flare rate between the groups (215). The second 
RCT was double-blinded, and evaluated a combined OC (35 μg 
ethinyl estradiol) versus placebo for 12 months. It included 183 
women with SLE with inactive disease, and analysis showed no 
statistical difference in flare rate (216).
A systematic review and meta-analysis evaluating the 
association between exposure to exogenous sex hormones (i.e., 
estrogens) and SLE (217), showed a significant association 
between hormonal replacement therapy (HRT) exposure and 
increased risk of SLE (RR: 1.96, 95% CI: 1.51–2.56, p < 0.001) 
(Figure  9). There was no association between HRT exposure 
and specific outcomes of disease. Six meta-analyses were run 
evaluating different outcomes: death, all flares, major flares, 
thrombosis, and coronary disease. None were significant (217). 
Moreover, analyses seeking an association between OC exposure 
FiGURe 9 | Association between hormonal replacement therapy (HRT) exposure and risk of developing SLe. Forest plot of studies meta-analyzed. Final 
common effect size based on a random model. CI: confidence interval; SLE: systemic lupus erythematosus; HRT: hormonal replacement therapy. Adapted with 
authors’ permission from Ref. (217).
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and different SLE outcomes were not significant with the excep-
tion of a marginal result in a meta-analysis, including the SLE 
outcome for patients with “ever-use” status and stratified by age. 
In conclusion, HRT exposure increases the risk of SLE in healthy 
women. Considering the selection bias of the studies included in 
the meta-analysis, which in general, excluded women with high 
disease, or antiphospholipid antibodies (aPL-abs), or history of 
thrombosis, generalization of results in the present study was 
limited and the recommendations for using these on women with 
known SLE must be followed cautiously (217).
Another meta-analysis found no statistically significant asso-
ciation between OC exposure and RA risk (RR: 0.88, 95% CI: 
0.75–1.03) (218).
Like SLE, SS and AITD are also highly prevalent among women 
(219). Several studies have recognized gender-associated charac-
teristics of disease and severity. For instance, women with SS have 
more anti-Ro antibodies and Raynaud’s phenomenon than men 
(220). Additionally, men with SS are at higher risk for lymphoma 
and neurological involvement than women. Accordingly, male 
gender is considered a risk factor for lymphoma in patients with 
SS (213, 221, 222). Additionally, AITD represents the main cause 
of hypothyroidism during pregnancy ranging between 5 and 20% 
in prevalence with an average of 7.8% (223).
Larger trials are required to assess the long-term effects of 
hormone therapy (e.g., contraception or postmenopausal) on the 
course of ADs and to identify patient characteristics associated 
with an increased risk of flares in hormone therapy exposure.
PolyA in the Context of Autoimmune 
ecology
As previously mentioned, the fact that ADs share several clinical 
signs and symptoms (i.e., subphenotypes), physiopathological 
mechanisms, and genetic factors has been called autoimmune 
tautology (12). The clinical evidence of autoimmune tautology 
highlights the co-occurrence of distinct ADs within an individual 
and becomes known as PolyA. Although there are several studies 
evaluating AE through the various ADs, there are few clinical stud-
ies of specific shared environmental factors favoring PolyA (224). 
Some examples of specific associated factors are shown below.
Vitamin D Levels and PolyA
T1DM and MS, two organ-specific ADs, frequently occur 
together (i.e., PolyA) in the Sardinian population (225). Patients 
with MS in Sardinia have a sixfold higher risk of T1DM than 
healthy controls. Although the frequency of the risk HLA group 
(HLA-DRB1*03) associated with T1DM and MS is highly 
increased in Sardinia, this genetic group does not seem to account 
for all T1DM–MS PolyA. Rather, the environment may be the 
most relevant element determining this risk, perhaps in a setting 
where susceptibility haplotypes do not decrease the chance of co-
occurrence of the two (226). Vitamin D is a shared environmental 
factor evaluated for these conditions. There is evidence showing 
a preventive role of vitamin D in MS and T1DM. A latitudinal 
gradient characterizes both diseases. T1DM and MS become 
increasingly common as distance from the equator increases and 
implicates common factors, such as Vitamin D deficiency (226). 
Although this environmental factor is shared, it has not been 
systematically evaluated in individuals who have this PolyA.
Recently, a study in celiac disease (CD) was done on 145 
patients searching for PolyA prevalence and related risk factors. 
The study participants were divided into two groups. Group 1 was 
the CD-alone group consisting of patients without any other ADs, 
while group 2 was the PolyA group consisting of patients with one 
or more accompanying ADs. When the groups were compared 
in terms of demographic features and laboratory data, vitamin 
D deficiency was the environmental factor associated with PolyA 
along with the following risk factors: female gender, family his-
tory for ADs, antigliadin IgG positivity, antinuclear antibody 
positivity ≥1/80 titer, and any musculoskeletal disease (227).
A retrospective cross-sectional study enrolled 133 women 
with recurrent pregnancy loss (RPL) for a 2-year period together 
with laboratory experiments (228). Sixty-three of them (47.4%) 
had low vitamin D levels (<30 ng/ml). The prevalence of aPL-
abs (anticardiolipin IgG and IgM) was significantly higher in 
the low vitamin D group (VDlow) (39.7%) than in the normal 
group (VDnl) (22.9%) (OR: 0.22, 95% CI: 1–4.7, p  =  0.05). 
Furthermore, anti-ssDNA (19.0 versus 5.7%, OR: 3.76, 95% CI: 
1.1–12.4, p = 0.05) and anti-thyroperoxidase antibody (33.3 ver-
sus 15.7%; OR: 2.68, 95% CI: 1.2–6.1, p = 0.05) were significantly 
higher in VDlow than in VDnl. Although authors did not study 
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the clinical confirmation of AITD, antiphospholipid syndrome 
(APS), and SLE through validated clinical criteria in the whole 
group, a serologic PolyA of AITD and SLE is displayed in a highly 
APS-potential group of patients (RPL with aPL-abs positivity). 
Since autoantibodies are predictors of disease, it is important to 
vigilantly following the clinical course of patients with RPL and 
VDlow for prediction of PolyA (APS plus AITD and SLE).
For APS and SLE PolyA, a relationship between vitamin D lev-
els and the co-ocurrence of these diseases has also been evaluated. 
Serum vitamin D levels were measured in 179 European APS 
patients and 141 controls (229). Of these, 113 APS patients were 
diagnosed with primary APS (pAPS) and 66 with the previously 
so-called APS secondary to SLE (i.e., PolyA). The mean levels dif-
fered between patients with APS alone (18 ± 9 ng/ml) and PolyA 
with SLE who disclosed lower levels of vitamin D [14 ± 8 ng/ml 
(p = 0.004)]. However, upon individual analysis, both levels were 
significantly lower than that for the controls.
Schoindre et  al. (230), evaluated serum 25(OH) Vitamin D 
levels in 170 patients with SLE who were prospectively followed 
up for 6 months. In a multivariate analysis contrasting with the 
previously mentioned results, absence of defined APS (p = 0.002) 
was one of the predictive factors of lower 25(OH)D levels, which 
showed an opposite relationship between low Vitamin D levels 
and PolyA with APS. These contrasting results should be analyzed 
carefully because there are few studies evaluating the influence of 
vitamin D levels in APS–SLE PolyA.
Similarly, Schneider et al. (231) evaluated 25(OH)D levels and 
cytokine profiles in 172 patients with SLE. There were 11 patients 
(6.4%) having PolyA with SS and the same number with APS. 
Although the main focus of the study was not the 25(OH)D levels 
in those PolyA patients, no associations were found between the 
presence of the previously so-called secondary APS nor second-
ary SS and vitamin D concentration.
All of the above results are linked to the fact that Vitamin D 
interacts with the immune system. It takes part in the regulation 
and differentiation of immune system cells directly and indirectly. 
Current data link vitamin D deficiency to many ADs, including 
T1DM, MS, inflammatory bowel disease, SLE, and RA. It is 
essential for part in the genetic regulation of cytokine production, 
VDR expression and affects biological processes by which these 
cells interact. Overall, vitamin D confers an immunosuppressive 
effect. Vitamin D has been shown to be clinically beneficial for 
animal models, and initial observations indicate that vitamin D 
supplementation may help prevent MS and T1DM (232). Further 
research is expected regarding the interaction between Vitamin 
D levels and PolyA.
Cigarette Smoking and PolyA
There are few or no studies designed to evaluate the relationship 
between cigarette smoking and PolyA. Nevertheless, this asso-
ciation has been evaluated as a secondary end point in studies 
researching PolyA globally.
A recent publication (233) analyzed the association between 
smoking and aPL-abs in SLE patients and explored the relation-
ship between smoking, aPL-abs, and vascular events (arterial 
and venous, VE). Out of a total of 367 SLE patients evaluated, 
118 were aPL-abs positive at inclusion. In regression-adjusted 
models, regular smoking was associated with aCL IgG, aβ2GP1 
IgG, LA, and triple aPL-abs positivity. Furthermore, former and 
current smokers were more likely to have a history of arterial 
events than never smokers.
A possible explanation for these results is that smoking may 
contribute to oxidative alterations, which, in genetically predis-
posed individuals, may give rise to an autoimmune response, 
epitope spreading, and induction of aPL-abs resulting in the 
SLE–APS PolyA and its association with cardiovascular events.
There are various studies showing the independent relation-
ship between smoking, APS or aPL-abs, and the specific car-
diovascular compromise subphenotype in SLE patients. Recently, 
Fernández-Nebro et  al. (234), identified smoking (OR: 1.48, 
95% CI: 1.06–2.07) and aPL-abs (OR: 1.57, 95% CI: 1.13–2.17) 
among other independent variables as risk factors for CV events 
through a multivariate analysis. The study involved 374 SLE 
patients (10.9%) from a total of 3,658 patients, who suffered at 
least one CV event. In addition, Ahmad et al. (235) evaluated the 
strength of association between traditional cardiovascular risk 
factors and carotid plaque development in 200 women with SLE 
and 100 controls. When combined in a final model, classic and 
SLE-related factors, they showed pack-years of smoking as well 
as serologic PolyA (aCL and/or any LAC) among other variables 
(any azathioprine exposure, age, and previous arterial events) as 
predictors of subclinical atherosclerosis. Likewise, in a multi-
ethnic SLE cohort (LUMINA) of 570 patients (236), 51 developed 
at least 1 venous thrombotic event after SLE diagnosis. Through a 
cox proportional hazard model, an independent association with 
smoking and positivity for LAC was demonstrated among other 
variables related to venous thrombosis.
Additionally, an independent association between APS PolyA 
(OR: 4.71, 95% CI: 1.81–12.2, p < 0.001) and smoking/coffee 
interaction (OR: 1.82, 95% CI: 1.05–3.13, p = 0.03) with CVD was 
previously shown in a cohort of 310 patients with SLE through a 
logistic regression model (166).
In a Colombian cohort of 376 patients with SLE (237), we 
evaluated the PolyA with autoimmune hypothyroidism and its 
related factors. Multivariate analysis and a classification and 
regression tree model (CART) were used to analyze data. After 
adjusting for gender and duration of disease, ever smoking (AOR: 
6.93, 95% CI: 1.98–28.54, p =  0.004), and PolyA with SS were 
persistently associated with AITD. Ever-smoking exposure as 
environmental factor was confirmed as a main factor associated 
with AITD PolyA in SLE patients through the CART model 
(Figure 10).
The association between smoking exposure and PolyA has 
been seen not only in SLE but also in other ADs. For example, 
the coexistence of ADs (i.e., PolyA) in SS and related factors was 
evaluated earlier in a cross-sectional study involving 410 patients. 
Of these, 134 (32.6%) had PolyA. In the regression analysis, 
duration of disease, positive smoking status (AOR: 2.86, 95% 
CI: 1.18–6.94, p = 0.02), and a history of spontaneous abortions 
remained significantly associated with PolyA (238).
Lastly, 955 consecutive RA patients (1987 ACR criteria) and 
their nuclear families were included in a single-center cohort 
study (239). The history of 23 ADs, the factors related to PolyA, 
and familial autoimmunity were investigated. The mixed cluster 
FiGURe 10 | Predictive factors associated with AiTD PolyA in SLe. Sjögren syndrome and ever smoking are the main factors associated with the development 
of AITD in SLE. AITD, autoimmune thyroid disease; PolyA, Polyautoimmunity; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome. Adapted from Ref. (237).
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methodology, based on multivariate descriptive methods, was 
used to summarize sets of related variables with strong associa-
tions and common clinical context. Then, for each set of related 
variables, new cluster variables (NCV) were derived for each 
patient. This was done on two sets of variables: the first were 
variables related to toxic substances consumed by patients from 
which we derived the toxic consumption profile as NCV; and the 
second was related to severity variables from which we derived 
the NCV of severity profile. The X2 and Fisher’s exact tests were 
done to establish differences between categorical variables 
(original and NCV) and PolyA. There were 130 (13.6%) patients 
who met the classification criteria for at least one other AD. Main 
factors influencing PolyA were familial autoimmunity, familial 
RA, and toxic consumption profile. For toxic consumption 
profile NCV, the proportion of PolyA in RA patients increases 
with more severe toxic exposure (no toxic consumption, followed 
by just coffee consumption exposure, then by coffee plus tobacco 
exposure, and finally, by coffee consumption plus hair dye).
A summary of the effects of cigarette smoking on the develop-
ment of ADs is shown in Figure 11.
Socioeconomic Status, Infections, and PolyA
As mentioned previously, several factors, such as SES, may explain 
differences in the prevalence of immunological disorders based 
on time and geographical distribution. Research on the influence 
of SES in PolyA is scarce. The influence of SES on the course of 
ADs in admixed and heterogeneous socio-demographic popula-
tions was evaluated in a cross-sectional analytical study in which 
1,096 consecutive patients with RA (n = 678), SLE (n = 258), and 
SS (n = 160) were included. Significant association between low 
SES and a stronger autoimmune response was observed (240). In 
addition, low SES influences the presence of arthritis, Raynaud’s 
phenomenon, and discoid lupus in SLE. As expected, an asso-
ciation between low SES and low educational level was observed 
in SLE and SS; while in RA, a low SES was also associated with 
housewives. The association between PolyA and low SES in SS 
patients (OR: 3.692, 95% CI: 1.49–9.18, p =  0.005) should be 
highlighted. These results could be related to the admixture of 
the evaluated population, environmental factors, or the quality of 
health insurance and deserve further research. The results of this 
study contrast with those of others. For instance, PolyA between 
RA and AITD plus associated factors was evaluated in a cohort 
of 800 RA patients (241). The prevalence of AITD in RA patients 
was 9.8%. A lower AITD frequency was found in the lowest 
educational level compared to the highest one. Therefore, a low 
educational level (a surrogate of low SES) was positively associated 
with AITD–RA PolyA (OR: 0.16, 95% CI: 0.03–0.88, p = 0.036). 
These results should be analyzed in the context of the mentioned 
“hygiene hypothesis” or a high infectious agent exposure (expo-
sure is interpreted as a poor hygiene problem). Epidemiological 
studies indicate a direct link between the decreasing infectious 
burden and the rising incidence of immunological disorders 
FiGURe 11 | Cigarrete smoking and autoimmunity. In predisposed individuals carrying certain autoimmune alleles at HLA-DRB1, PTPN22, and PADI4 genes, 
cigarette smoke triggers citrullination by activating PAD enzyme, a mechanism that is estrogen dependent. Citrullinated proteins act as auto-antigens and induce the 
formation of anticitrullinated protein autoantibodies (ACPAs) by autoreactive B cells. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), released during cigarette smoking, 
acts as the best-known ligand for aromatic hydrocarbon receptor (AhR). AhR activation induces boosts T helper 17 (Th17) cells. Nicotine stimulates the α7-nicotine 
acetylcholine receptors (α7nAChRs), and increases TNFα, IL-6, IL-8, and IL-1 synthesis. The effect on T regulatory (Treg) function is controversial. All of these 
molecular pathways are responsible for the clinical manifestations listed on the right. PAD, peptidylarginine deiminase; SE, shared epitope; DC, dendritic cell; MS, 
multiple sclerosis; PBC, primary biliary cirrhosis; AITD, autoimmune thyroid disease; RA, rheumatoid arthritis; DMARD, disease-modifying antirheumatic drug; CVD, 
cardiovascular disease; ADs, autoimmune diseases; PolyA, polyautoimmunity; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; aPL-abs, 
antiphospholipid antibodies.
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(196). Also, social and environmental exposures directly impact 
immune tolerance and response. Furthermore, several epidemio-
logical studies have investigated the protective effect of infectious 
agents in allergy and ADs.
Although the relationship between infectious disease and 
autoimmunity was not intended to be part of this review, some 
examples regarding the association between infectious disease 
and PolyA are shown below. EBV and CMV are notorious as 
they are consistently associated with multiple ADs. A cohort of 
1,595 serum samples from 23 different AD groups was screened 
for evidence of prior infection with EBV and CMV (242). When 
compared to healthy controls, a significant increase in titers of 
EBV Viral Capsid Antigen IgG was observed in sera of patients 
with SLE–APS PolyA as well as in both diseases separately and 
in patients with other, single ADs (e.g., RA, MS, etc.). Moreover, 
samples from 82 consecutive SS patients, and 139 healthy controls 
were analyzed for infectious serology and autoantibodies as well 
as for relevant genetic mutations (TAP genes) and cytokine 
levels (243). Vasculitis PolyA among SS patients was significantly 
related to the presence of Saccharomyces cerevisiae antibody IgG 
(OR: 6.5, 95% CI: 1.14–36.78, p =  0.05). No other infectious 
autoantibodies were related to PolyA.
In contrast to this, when evaluating sera from 260 individuals 
(120 SLE patients, 140 geographically matched controls) for titers 
of infectious antibodies (five EBV-Abs), differences in titers from 
SLE-associated APS were not detected (244).
The results presented here agree with clinical evidence for all 
of the current theories on how infections could cause AD. Recent 
evidence suggests that microbe-activating specific innate immune 
responses are critical while antigenic cross-reactivity may per-
petuate immune responses leading to chronic autoinflammatory 
disease (245). The data regarding cross-talk between PolyA as 
an expression of specific activated immunological pathways and 
infectious agents suggest that infections may play both a causative 
role and a protective role in the pathogenesis of ADs.
Organic Solvents and Autoimmunity
Solvents are liquids that dissolve a solid, liquid, or gas and are 
broadly classified into two categories: organic and inorganic. OSs 
are compounds with carbon-containing molecules. They may be 
broken down further into aliphatic-chain compounds, such as 
n-hexane, and aromatic compounds with a six-carbon ring, such 
as benzene or xylene. Common uses of OSs are dry cleaning (e.g., 
tetrachloroethylene), paint thinner (e.g., toluene, turpentine), 
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nail polish removers, and glue solvents (acetone, methyl acetate, 
ethyl acetate), spot removers (e.g., hexane, petrol ether), deter-
gents (citrus turpenes), perfumes (ethanol), nail polish, and 
chemical synthesis, etc. (246). OSs are capable of altering cellular 
proliferation, apoptosis, and tissue-specific function. Both the 
amount and duration of OS exposure are essential in pathology 
causality. Chronic exposure to OSs might lead to deposits in an 
organ and consequently to immune infiltration similar to what is 
observed in ADs. The self-proteins that are modified by OSs may 
become immunogenic, recognized as foreign and, thus, initiate 
an inflammatory response and tissue injury (246).
Research in this area began in the 1950s after case reports of 
patients who developed a scleroderma-like syndrome after expo-
sure to vinyl chloride, epoxy resins, trichloroethylene, perchloro-
ethylene, or mixed solvents (11). The evidence of an association 
between exposure to OSs and developing AD was recently ana-
lyzed through a systematic literature review and meta-analysis. 
Even though the individual meta-analyses (i.e., each AD consid-
ered separately) showed significant association for MS, primary 
systemic vasculitis, and SSc, the direction and significance of this 
association did not change when all ADs, considered as a single 
trait, were analyzed (OR: 1.54, 95% CI: 1.25–1.92, p = 0.001). To 
our knowledge, this is the first evaluation of all ADs as a group 
with respect to OSs exposure through a meta-analysis. Therefore, 
the fact that ADs might share several common mechanisms (i.e., 
the autoimmune tautology) is reinforced (246).
Nevertheless, a recent review of systematic reviews and 
meta-analyses evaluating environmental risk factors and MS 
did not show a significant association (247). Likewise, the 
occurrence of MS among subjects exposed to anesthetic agents 
was compared to that of those who have never been exposed. 
This was based on previous evidence that exposure to anesthetic 
agents, some of which are chemically related to organic solvents, 
may affect the risk of MS. Therefore, based on two population-
based, case-control studies, one with incident cases (1,798 
cases, 3,907 controls) and one with prevalent cases (5,216 cases, 
4,701 controls), no association was found between occupational 
exposure to anesthetic agents and risk of MS (248). By contrast, 
other studies evaluating the relationship between occupational 
exposure and risk of MS have shown positive associations. In 
a matched case-control study of 276 first clinical diagnosis of 
central nervous system demyelination cases and 538 controls 
done in Australia (2003–2006), Valery et  al. examined the 
association between occupational exposure and risk of central 
nervous system demyelination. Among women, there was an 
increase in central nervous system demyelination risk associ-
ated with 10 or more years of exposure to livestock (AOR: 2.78, 
95% CI: 1.22–6.33) or 6 or more years of farming (AOR: 2.00, 
95% CI: 1.23–3.25; adjusted for number of children) (249). 
Horwitz et  al. estimated the occupational risks in relation to 
MS in an open insurance cohort (all payouts for critical illness 
insurance from 2002 to 2011 were continuously registered). The 
MS incidence showed signs of occupation having an overall 
effect on the risk of MS. The high frequency found within the 
agricultural segment was attributed to dairy operators, whose 
incidence of MS was 2.0 times higher than the rest of the study’s 
population (95% CI: 1.2–3.0) (250). Furthermore, Magyari et al., 
studied whether occupation or physical or social environment 
influenced the risk of MS differently in women than in men in 
a cohort consisting of 1,403 patients (939 women, 464 men), 
identified through Danish MS registry (2000 and 2004), and up 
to 25 matched controls (251). They found a slight albeit statisti-
cally significant excess for six female MS patients who had been 
employed in agriculture: OR: 3.52; 95% CI: 1.38–9.00, p = 0.008 
(0.046 when corrected for multiple significance) although the 
number of cases was small.
Concerning SSc, recent publications have shown an associa-
tion between OSs exposure and SSc. Marie et al. (252) evaluated 
the relationship between SSc and occupational exposure between 
2005 and 2008 in 100 patients with a definite diagnosis of SSc 
and 3 matched controls for each patient. Higher ORs for SSc 
were found for white spirit (p  =  0.0001), aromatic solvents 
(p = 0.0002), chlorinated solvents (p = 0.014), trichlorethylene 
(p = 0.044), ketones (p = 0.002), and welding fumes (p = 0.021). 
In addition, in a prospective study involving 142 SSc patients, 
Marie et al. (253) showed that patients exposed to solvents more 
frequently developed diffuse cutaneous SSc (p = 0.001), digital 
ulcers (p = 0.01), interstitial lung disease (p = 0.02), myocardial 
dysfunction (p  =  0.04), and cancer (p  =  0.003). Moreover, 
these patients were more frequently anti-Scl 70 positive and 
anticentromere negative. Furthermore, based on those results, 
some researchers have recently suggested that the association 
between SSc and occupational exposure be legally recognized as 
an  occupational disorder (254).
Lastly, Li et al. (255) investigated possible associations between 
occupation and hospitalization for SLE in a nationwide database 
(Swedish Census to the Hospital Discharge Register 1970–2008). 
A total of 8,921 male and 42,290 female hospitalizations for SLE 
were analyzed. Higher risks [standardized incidence ratios (SIR)] 
among men with the same occupation (SIR > 2.0) were present 
among workers exposed to OSs in two consecutive censuses: shoe 
and leather workers (6.93), plumbers (2.21), chimney sweeps 
(4.54), and military personnel (3.01), etc.
To summarize, the recent expert panel (10) was confident 
regarding evidence supporting an association between solvent 
exposure and developing SSc. They agreed that general solvent 
exposure may also contribute to MS, but more research is needed 
using improved exposure assessment methods.
In conclusion, an association between OSs exposure and ADs 
is observed. OS exposure has not yet been sufficiently studied, 
and to clarify its role in ADs pathogenesis, its relationship with 
genetics needs to be studied, whether with respect to protection 
or susceptibility to each AD and the effects on the autoimmune 
process.
vaccines
Vaccines represent the most successful and sustainable tactic to 
prevent and counteract infection. A vaccine improves immunity 
to a particular disease upon administration by inducing specific 
protective and efficient immune responses in all of the receiving 
population. The main known factors influencing the observed 
heterogeneity for immune responses induced by vaccines are 
gender, age, ethnicity, co-morbidity, immune system, and genetic 
background (256).
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Autoimmunity is a concern for many vaccines, although AD 
presentation among immunized individuals is rarely observed. 
Nevertheless, and as mentioned, ASIA entails autoimmune con-
ditions appearing after the exposure to an external stimuli of an 
adjuvant, including vaccines (257). In spite of some controversy 
about the diagnosis and classification criteria of this syndrome 
(258), we have observed and discussed patients who developed 
autoimmune conditions after quadrivalent human papillomavi-
rus vaccination (259). However, because of relatively low baseline 
incidence of many autoimmune conditions, large post-marketing 
and adequately powered studies are required to evaluate any 
increased risk of ADs after vaccination. In fact, in most of the 
clinical trials evaluating vaccines, a systematic screening for ADs 
is not performed (i.e., testing for autoantibodies and evaluation 
of familial autoimmunity).
The incidence of narcolepsy, a sleep disorder characterized by 
loss of hypothalamic hypocretin (orexin) neurons, was increased 
after the pandemic AS03 adjuvanted H1N1 vaccination in Swedish 
and Finish but not in Italians (260). The clue for the observed side 
effects could be related to one type of vaccine, since not all the 
vaccines against H1N1 were associated with such complication. 
In fact, the vaccine inducing narcolepsy was suspected to trigger 
antibodies that can also bind hypocretin receptor 2 (261).
There is no a single mechanism explaining how a vaccine may 
induce AD. Theoretically, vaccines could trigger autoimmun-
ity by means of cytokine production, anti-idiotypic network, 
expression of human histocompatibility leukocyte antigens, 
modification of surface antigens and induction of novel antigens, 
molecular mimicry, bystander activation, epitope spreading, and 
polyclonal activation of B cells (262).
There are several case reports of ADs following vaccines (45); 
however, due to the limited number of cases, the different classifi-
cations of symptoms, the long latency period of the diseases, and 
bias in data interpretation, every attempt for an epidemiological 
study has so far failed to deliver a connection. Despite this, efforts 
to unveil the connection between the triggering of the immune 
system by vaccines and the development of ADs should be under-
taken (257).
On the other hand, in patients with AD receiving immunosup-
pressive therapy, vaccinations are often not offered or provided 
for a variety of reasons, including the fear of complications or 
vaccine-related illnesses, a concern for disease flare or reactiva-
tion, a perceived lack of effectiveness, or a misunderstanding of 
current vaccine guidelines (263). Patients with ADs often show 
decreased immune responsiveness, which in turn would make 
them vulnerable to infection given their underlying disease and 
frequent use of immunosuppressive drugs. A recent review high-
lights that all recommended vaccines may be given to patients 
before the start of immunosuppressive therapy (264, 265). All 
inactivated-killed vaccines should be provided to patients with 
AD, as they provide significant morbidity and mortality benefits. 
Inactivated-killed vaccines have not been shown to be associ-
ated with disease flares in large studies adequately powered to 
determine this effect. Live vaccines should be used mainly before 
the start of immunosuppressive therapy and used with caution on 
patients on active immunosuppressive therapy based on national 
guideline recommendations (264).
Conclusions and Perspectives: 
Personalized Medicine and Risk Prediction
Personalized (or precision) medicine, taking account of human 
individuality, has shown great promise to transform medical care. 
Since most of genetic factors associated with ADs confer a modest 
risk of ADs (266) and the immune system is very much shaped by 
the environment (13), inclusion of the AE in disease etiology and 
health will improve the way personalized medicine is currently 
conceived and applied (267).
Better understanding of the complex gene–environment 
interactions involved in the development of ADs together with 
the study of epigenetics (which was beyond the scope of this 
review) will provide insight into personalized interventions for 
these common and sometimes devastating diseases. Algorithms, 
constructed based on data gathered at the population level, can 
shed light on how the parts work together and the causal rela-
tionships between them, allowing strategies for prediction and 
prevention of ADs.
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